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ABSTRACT 
Immune cells actively take part to the tumor microenvironment, where they play several roles 
in the multistep process of carcinogenesis. Among the tumor-infiltrating immune cells, 
myeloid cells represent a “double-edged sword” for cancer. Indeed, they can both promote or 
inhibit cancer initiation and progression. Neutrophils have long been viewed as short-lived 
cells, pivotal for the elimination of extracellular pathogens, with a limited role in the 
orchestration of the immune response. However, recent lines of evidence have challenged this 
limited point of view, revealing a number of unexpected functions for neutrophils in several 
pathological contexts. Indeed, neutrophils were also found among inflammatory cells 
infiltrating cancer tissues, such as colorectal cancer (CRC). Today, the functional roles of 
neutrophils in cancer and the association between neutrophil infiltration, clinicopathological 
features and outcome of CRC patients remain to be clarified. Here, we found that neutrophils 
are recruited within CRC tissues through a spatiotemporal dynamism. Infiltration of 
neutrophils increased from stage I to stage III CRC and decreased at stage IV. In a large 
cohort of stage III CRC, neutrophil infiltration was preferentially found in the intratumoral 
compartment compared with the invasive margin. Higher density of neutrophils within the 
tumor was found to be an independent prognostic factor for better patients’ outcome (n=128, 
Stage I-Stage IV CRC) and a predictive factor for 5-FluoroUracyle chemotherapy response in 
Stage III CRC patients (n=178). Moreover, CRC cell lines released soluble factors, which 
promoted neutrophil chemotaxis and survival. In turn, neutrophils displayed a cytostatic 
activity towards CRC cell lines. Our data suggest that neutrophils are critical components of 
antitumor immunity and that neutrophil infiltration within tumors could be a useful predictive 
marker to identify patients with cancer who would likely benefit from chemotherapy. 
Therefore, neutrophils have to be considered as central participants in the regulation of the 
innate and adaptive immune responses, with important roles in the resolution or exacerbation 
of various pathologies, including cancer.  
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INTRODUCTION 
 
Immune cells are important participants of the tumor microenvironment, where they play 
several roles in all the steps of cancer development. Among the immune cells infiltrating 
tumors, myeloid cells can play a dual role in sculpting cancer behavior. Indeed, they can 
promote or inhibit cancer initiation and progression. Neutrophils have recently emerged as 
key component in the regulation of the innate and adaptive immunity in several 
inflammatory conditions, including cancer. 
I. 1. The hallmarks of cancer 
The gradual transformation of a normal cell to a neoplastic state is complex and requires 
the acquisition of a series of skills necessaries to overcome the multiple natural 
mechanisms that control cell homeostasis, growth and proliferation. For instance, 
accumulation of genetic mutations can overwhelm mechanisms naturally designed to 
control DNA integrity and, therefore, lead to malignant cell transformation. In 2000, 
Hanahan and Weimberg proposed that all cancers share six common traits, called 
“hallmarks”, responsible for the transformation of a normal cell (Hanahan and Weinberg, 
2000) (Figure 1). These hallmarks are: self-sufficiency in growth signals; evading growth 
suppressors; evading apoptosis; enabling replicative immortality; sustained angiogenesis; 
activating invasion and metastasis. 
Following this first description, four new hallmarks have been added. They consist in the 
deregulation of the metabolic pathways, the capacity of cancer cells to evade the immune 
system, the role of chronic inflammation and the presence of unstable DNA (Figure 2) 
(Hanahan and Weinberg, 2011). The role of the immune system in preventing malignant 
transformation consists of three functions: a) eradication of oncogenic viruses; b) 
prevention and control of tumor-promoting inflammation; c) direct recognition and 
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destruction of neoplastic cells, a process initially referred as “cancer immunosurveillance” 
(Hanahan and Weinberg, 2011).  
I. 2. Cancer Immunoediting: the immunosurveillance hypothesis revisited 
In 1909 a protective role for the immune system in defense against cancer was proposed 
by Paul Ehrlich (Ehrlich, 1909). However, knowledge about mechanisms and functions of 
the immune system were immature to sustain this hypothesis. Fifty years later, Burnet and 
Thomas have elaborated the “immunosurveillance hypothesis”, suggesting that the adaptive 
immune system was able to prevent tumor development in immunocompetent hosts 
(Burnet, 1957; Thomas, 1959). However, further findings did not support this hypothesis 
and the immunosurveillance theory was abandoned for years (Stutman, 1974). Only in late 
Nineties and with the advent of genetically modified animal models this theory came to 
light again. In fact, evidence that mice genetically deficient in IFN-γ signaling (Ifngr1-/-) or 
in adaptive immune components (e.g. Rag2
-/-
) displayed higher spontaneous or carcinogen-
induced tumor susceptibility renewed the interest in the role of the immune system in 
defense against tumor development (Engel et al., 1996; Engel et al., 1997; Kaplan et al., 
1998). Few years later, another line of evidence led to a further revision of the 
immunosurveillance hypothesis. In fact, chemically induced sarcomas from 
immunodeficient mice (Ifng
-/- 
or Rag2
-/-
) where rejected in immunocompetent mice, 
whereas sarcomas from immunocompetent mice were not rejected (Shankaran et al., 2001). 
This result suggested that tumors occurring in absence of a functional immune system were 
more immunogenic compared to analogous tumors arising in immunocompetent mice and 
that the immune system was able not only to detect tumor cells and potentially eliminate 
them, but also to shape tumor features, a process called “tumor immunogenicity” 
(Shankaran et al., 2001). These observations put the basis of the cancer immunoediting 
theory, as the property of the immune system to modify cancer behavior and 
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immunogenicity, articulated in three phases: elimination, equilibrium and escape (Figure 3) 
(Schreiber et al., 2011). 
The elimination phase is a reviewing of the immunosurveillance. This concept defines 
the capacity of both innate and adaptive immunity to identify transformed cells and 
eliminate them. In the best epilogue, if tumor cells are eliminated, the elimination phase can 
be sufficient. In the equilibrium phase, the immune system maintains the tumor in a 
functional state of dormancy and the tumor can rest latent in the host for long time (Dunn et 
al., 2002). Under the pressure of the immune system, tumor clones can lack 
immunodominant rejection antigens via a process called “immunoselection” of the most 
immunoevasive clones. This is the escape phase, in which tumor cells have acquired a 
number of mechanisms to evade immune system. As an alternative way to escape 
immunosurveillance, tumor cells use the immune cells to their advantage. In a so-called 
“immunosubversion” mechanism, tumor cells recruit immune cells and properly educate 
them to shut down the anti-tumor immune response, supporting tumor growth and 
dissemination. The immunosubversion process is the most evolved form of immunoescape 
(Zitvogel et al., 2006).  
Tumor-infiltrating immune cells have long been recognized by pathologists, mirroring 
inflammatory conditions arising in non-neoplastic tissues (Dvorak, 1986). Such immune 
responses were considered an attempt by the immune system to eliminate tumors. However, 
the tumor-associated inflammatory response had also the paradoxical effect of promote 
tumorigenesis and progression, favoring emerging neoplasias to acquire hallmark 
capabilities. In the next decade, several lines of research analyzed the connections between 
inflammation and cancer concluding that inflammatory immune cells display tumor-
promoting properties on neoplastic progression (Colotta et al., 2009; DeNardo et al., 2010; 
Grivennikov et al., 2010; Qian and Pollard, 2010). Indeed, in the most recent revision of 
cancer hallmarks, Hanahan and Weinberg described cancer associated inflammation as an 
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“enabling characteristic”, necessary to acquire the cancer hallmarks and to make possible 
the neoplastic transformation (Hanahan and Weinberg, 2011). 
II. CANCER RELATED INFLAMMATION 
Inflammation is a physiological process naturally occurring in tissues, following a stress, 
infection or damage (Medzhitov, 2008). In a controlled inflammatory response, specialized 
cells are recruited at the inflammatory sites to limit the insult and avoid the extent of the 
damage. Usually, inflammatory response is self-limited and homeostatic conditions are 
reestablished during the process of resolution of inflammation (Zamarron and Chen, 2011). 
However, inflammation can evolve to a chronic state, which was associated with the 
development of several human cancers (Grivennikov et al., 2010; Zamarron and Chen, 
2011). 
In 1860 Rudolf Virchov first observed leukocyte infiltration in neoplastic tissues and 
suggested a link between inflammation and cancer (Balkwill and Mantovani, 2001). A 
number of evidence coming from epidemiological studies and animal models have 
suggested that cancer and inflammation were linked (Mantovani et al., 2008). For instance, 
several cancer types are due to inflammatory reactions following infectious causes, such as 
Hepatitis C virus for Hepato-Cellular Carcinoma (HCC) or Helicobacter pylori for gastric 
cancer (Mantovani et al., 2008). However, also tumors without an inflammatory 
background present signs of “smoldering inflammation”. In fact, inflammatory cells and 
mediators are found in most tumors microenvironment (Mantovani et al., 2008). 
Chronic inflammation plays a role in all stages of tumorigenesis, including initiation 
(through genotoxic damage), promotion (favoring cell proliferation) and progression 
(promoting invasiveness and metastasis) (Grivennikov et al., 2010). Given these 
assumptions, it has been proposed that inflammation and anti-tumor immune response exert 
opposite effects on cancer development (Karin et al., 2002; Mantovani et al., 2008). 
However, cancer-related inflammation and anti-tumor immunity can co-exist in the same 
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tumor in a delicate balance, which can be altered in favor of one during the process of 
immunoediting (Bui and Schreiber, 2007). Moreover, inflammation exerts pivotal functions 
during tumor escape, when inflammatory cells, recruited at the tumor site and activated by 
cancer-derived molecules, suppress the anti-tumor immune response (Grivennikov et al., 
2010). Tumor cells can generate an immunosuppressive state through the inhibition of 
effector functions of immune cells or the active recruitment of regulatory immune cells 
(Vesely et al., 2011). For instance, many malignant cells constitutively produce small 
amounts of TNF- , which is known to enhance growth and spread of syngeneic, 
xenogeneic and carcinogen-induced tumors of skin, ovary, pancreas, pleural cavity and 
bowel (Balkwill, 2009; Schioppa et al., 2011). Malignant-derived TNF-  can also exert 
pro-tumorigenic functions targeting macrophages or T CD4
+
 cells (Charles et al., 2009; 
Hagemann et al., 2005). Tumor cells exert also systemic effects through the production of 
the immunosuppressive molecules TGF-β and IL-10, which inhibit dendritic cell (DC) 
activation as well as T cell and natural killer (NK) cell functions (Aruga et al., 1997; 
Wrzesinski et al., 2007). A number of non-neoplastic cells, which constitute the tumor-
associated stroma, such as fibroblasts and immune cells, take part in tumorigenesis as 
active contributors rather than passive bystander cells and actively contribute to the 
acquisition of cancer hallmarks (Dudas, 2015).    
III. TUMOR-INFILTRATING IMMUNE CELLS 
III. 1. Adaptive immune cells 
III. 1.1. T cells 
T cells are found in the tumor microenvironment of most solid tumors (Galon et al., 
2006; Senovilla et al., 2012). Both CD4
+
 T helper cells and CD8
+
 T cytotoxic cells can be 
present.  
CD8
+
 cytotoxic T cells (CTL) play a central role in tumor immune surveillance (Fridman 
et al., 2012). They express T cell receptors (TCRs), which interact with specific peptides 
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presented in the context of MHC class I (MHCI/pep) by the antigen presenting cells (APCs) 
(Cross et al., 2008). Together with the co-stimulatory signal derived from the interaction 
between CD28 on the T cell and CD80/CD86 on the APC, the MHCI/pep-TCR interaction 
activates T cells. In this favorable context and with the help of cytokines (e.g. IL-12, IFN-
), naive CD8
+
 T cells undergo clonal expansion and acquire effector functions, such as 
Granzyme and Perforin production, which finally destroy target cells (Hwang and Nguyen, 
2015). In the context of tumor immunosurveillance, APC, such as DC, can capture tumor 
antigens released from tumor cells or immunogenic dying tumor cells, a process induced by 
some forms of chemotherapy (Palucka and Banchereau, 2012; Zitvogel et al., 2013). DC 
process the antigens and present them in the context of MHC I, MHC II or non-classical 
CD1 molecules. Extracellular peptides can be presented to CD8
+
 T cells in the context of 
MHC I in a mechanism called cross-priming (Chen et al., 2004). Activated DC express 
cellular (such as co-stimulatory ligands) and soluble mediators (such as IL-12) for 
activation of CD8
+
 T cells (Scapini et al., 2002). CD8
+
 T cells undergo clonal expansion 
and differentiate in effector cells in secondary lymphoid organs, exit the organs and are 
recruited to the tumor microenvironment, where they exploit their effector functions and 
kill target cells (Banchereau and Steinman, 1998; von Andrian and Mempel, 2003). 
CD4
+
 T helper (Th) lymphocytes are an heterogeneous population of cells (Eyles et al., 
2006). The T helper cell subsets are defined by the production of cytokines and/or the 
expression of characteristic lineage defining transcription factors (Table 1).  Five principal 
subsets of Th cells have been identified: Th1, Th2 and Th17 cells, which respond to distinct 
classes of pathogens (Korn et al., 2007; Romagnani, 1997), regulatory T cells (Treg), which 
are involved in the process of tolerance (Sakaguchi, 2005) and follicular helper T cells 
(TFH) that provide help to B cells for antibody production (Crotty, 2011).  
Following the antigen-specific signal, mediated by the interaction between TCR and 
MHC II, and the co-stimulatory signal, mainly mediated by the interaction between CD28 
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on the T cell and CD80 and CD86 on the APCs, specific T helper subset polarization 
depends on the signal derived from the APCs, consisting in soluble or membrane-bound 
factors (Kapsenberg, 2003). Th1 cells are classically induced in presence of IL-12, mainly 
produced by cells infected by intracellular pathogens and following TLR activation (Netea 
et al., 2005; Nizzoli et al., 2013). They express the transcription factor T-bet and produce 
IFN-γ, which activates macrophages and NK cells to eliminate invading viruses and 
bacteria (Nizzoli et al., 2013; Romagnani, 1997). In contrast, in presence of IL-4, Th cells 
undergo Th2 differentiation. Th2 cells express the transcription factor GATA3, produce IL-
4, IL-5, IL-10 and IL-13, and play pivotal roles in defense against helminthic infection and 
in allergic responses (Robinson et al., 1992). Early studies in humans demonstrated that 
IFN-γ and IL-4 production were not exclusive, since some T cell clones co-produced both 
molecules (Maggi et al., 1992). Moreover, some T cells co-express the Th1 and Th2 
markers CXCR3 and CCR4 (Rivino et al., 2004), as well as the transcription factors T-bet 
and GATA3 (Peine et al., 2013). T cell plasticity was also demonstrated by the production 
of IL-10 in Th1 cells (Gerosa et al., 1996). This property was related to the capacity of Th1 
cells to prevent an uncontrolled immune response (O'Garra and Vieira, 2007). Thus, Th1 
cells can switch to an immunomodulatory IL-10-producing phenotype, named Type 1 
regulatory (Tr1)-like T cell, to maintain the integrity of the host (Roncarolo et al., 2001). In 
addition, in a mouse model of helminthic infection, Th2 cells were shown to give rise to 
BCL6
+
, IL-21
+
 and GATA3
+
 TFH (Glatman Zaretsky et al., 2009). TFH are professional B 
helper cells, which express the transcription factor BCL6 and the chemokine receptor 
CXCR5 and produce IL-21 in B cell follicles (Crotty, 2011). Murine Th2 cells, in the 
presence of TGF- , can switch to Th9 cells, which express the transcription factor PU.1, 
produce IL-9 and participate in the allergic response in asthma and helminthic infections 
(Anuradha et al., 2013; Chang et al., 2010; Veldhoen et al., 2008; Xie et al., 2012).  
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CD4
+ 
T cells contribute to anti-tumor or pro-tumor immunity in different ways 
(Blankenstein et al., 2012). They can sustain the activity of CD8
+
 T cells through the 
production of IL-2 and IL-12. Indeed, these cytokines promote CD8
+
 T cells expansion, 
activation and survival and improve the affinity of MHCI/peps to ameliorate CD8
+
 T cell 
response (Mescher et al., 2007). Moreover, the interaction between CD4
+
 T cell and DC 
presenting cognate MHCII/peps, can give rise to DC reconditioning, through interactions 
between CD40 on DC and CD40L on T cells. These interactions result in the up-regulation 
of a number of co-stimulatory signals and polarizing stimuli, such as IL-12 production, 
which in turn favor the activation of CD8 cells (Melief, 2008; O'Sullivan and Thomas, 
2003). CD4
+
 T cells play also a role in immunosurveillance independent of CD8
+
 cells 
since cytokines such as IL-2, IL-12 and IFN-  also activate monocytes, macrophages and 
DC, to display an anti-tumor response (Jacobson et al., 1995; Mucida and Cheroutre, 2010). 
In contrast, IFN-  can also trigger the expression of programmed cell death ligand (PDL-1) 
on cancer cells, which engages PD-1 on cytotoxic T cells, providing off signals and 
favoring tumor development (Sharpe et al., 2007) (Matsushita et al., 2012). Th2 cells retain 
a well-known tumor-promoting potential. In human and murine breast cancer, tumor-
promoting Th2 cells can be induced by IL-13 and TNF-  produced by OX40L-expressing 
DC, which in turn are activated in response to tumor-derived Thymic-Stromal 
lymphopoietin (TSLP) (Pedroza-Gonzalez et al., 2011). In murine models of breast cancer, 
CD4
+
 Th2 cells accelerated tumor growth through the production of IL-13 (Aspord et al., 
2007) and favored macrophage polarization toward a pro-tumorigenic phenotype, induced 
by the local production of IL-4 (Gocheva et al., 2010). In human breast and pancreatic 
cancers, the Th2 signature was increased in lymph nodes and associated with reduced 
survival (De Monte et al., 2011; Kristensen et al., 2012).  
Local production of cytokines and the expression of selected chemokine receptors by 
tumor infiltrating lymphocytes (TILs) define their homing, their activation and their 
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polarization states. For instance, CD8
+ 
T cells and Th1 cells express CXCR3 and CX3CR1 
that make them responsive to CXCL9 and CXCL10 and to CX3CL1, respectively. 
Moreover, the chemokines CXCL9 and CXCL10 are produced by cancer or stromal cells 
and promote anti-tumor responses by recruiting CD8
+
 and Th1 cells, as documented in 
colo-rectal cancer (CRC) (Mlecnik et al., 2010; Musha et al., 2005) (Zumwalt et al., 2014), 
renal cancer (Pan et al., 2006) and gastric cancer (Ohtani et al., 2009). Thus, within the 
tumor microenvironment, tumor and stromal cells modulate the microenvironment, which 
shape the immune infiltrate, towards a pro-tumor or anti-tumor response.  
CD4
+
 CD25
+
 regulatory T cells (Treg) express the transcription factor Foxp3 and include 
natural (acquiring regulatory functions in the thymus) or adaptive (induced in the periphery 
from mature CD4
+ 
T cells under the influence of TGF- ) Treg (Stephens et al., 2001; Tran 
et al., 2007). These cells are required to maintain self-tolerance and their functional 
specialization is shaped by the tissue microenvironment (Burzyn et al., 2013). Treg play 
important roles in tumor progression and accumulate in peripheral blood and tumor of 
cancer patients (Halvorsen et al., 2014) (Whiteside, 2012). Tumor-infiltrating immune cells 
or tumor cells themselves produce soluble factors able to recruit Treg, such as CCL17 or 
CCL22 (Mizukami et al., 2008; Sun et al., 2015; Wertel et al., 2015). Increased recruitment 
of Treg contributes to a tumor-promoting microenvironment (Whiteside, 2013; Zou, 2006). 
Indeed, through the production of immunomodulatory cytokines, such as IL-10 and TGF-β, 
Treg efficiently dampen the functions of CD8
+
 T cells, including IFN-γ production 
(Roncarolo et al., 2006). Treg express high levels of the IL-2 receptor IL-2R , which acts 
as a decoy for IL-2 and reduce the local levels of this cytokine, impairing T cell activation 
and proliferation (Shevach, 2009). Treg affect also DC development. Indeed, they prevent 
DC maturation and induce the expression of IL-10, as well as immunosuppressive 
molecules of the B7-H family, in DC (Mahnke et al., 2007). Priming of T cells by these 
tolerogenic DC results in T cells tolerance in the form of anergy or clonal deletion 
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(Maldonado and von Andrian, 2010; Raimondi et al., 2007). Interestingly, the 
immunoregulatory functions of Treg can be also beneficial for the host. Indeed Treg limit 
the inflammatory component of tumors and it has been hypothesized that this mechanism is 
responsible for the positive prognostic effect exerted by the T regulatory infiltrate in CRC 
(Fridman et al., 2012). 
Th17 cells are induced by the combination of IL-1 , IL-6, TGF-  and IL-23, express the 
transcription factors ROR-c in humans and ROR t in mice respectively, are characterized 
by the production of IL-17 and play important roles in combating extracellular pathogens 
and fungi (Annunziato et al., 2007; Unutmaz, 2009) (Manel et al., 2008). In cancer, Th17 
cells can exert pro- or anti-tumor functions depending on the tissue microenvironment. The 
major pro-tumor functions of Th17 cells are due to angiogenesis promotion and recruitment 
of tumor-promoting myeloid cells (Wei et al., 2012). For instance, in a murine model of 
subcutaneous fibrosarcoma cell graft, the increased expression of IL-17 was associated with 
tumors displaying higher vessel density, due to the increased expression of VEGF, 
keratinocyte-derived pro-angiogenic chemokines (CXCL1 and CXCL2) and prostaglandins 
by fibroblasts and stromal cells (Numasaki et al., 2003). In some tumor murine models, 
upon treatment with anti-VEGF antibodies higher tumor infiltration by mature Th17 was 
found, associated with higher CD11b
+
Gr1
+ cells and amplified expression of both G-CSF 
and IL-17. This “IL-17-G-CSF” axis was associated with angiogenesis independent of anti-
VEGF therapy and promotion of tumor growth via the recruitment of immune-suppressive 
and pro-angiogenic CD11b
+
Gr1
+ myeloid cells (Chung et al., 2013). In addition, in a mouse 
model of intestinal spontaneous carcinogenesis, microbial products derived from the 
adenoma-induced epithelial barrier alterations, induced IL-23 production in myeloid cells, 
which in turn activated an IL-17-mediated pro-tumoral response (Grivennikov et al., 2012). 
In humans, IL-17 was responsible for the recruitment of neutrophils in peritumoral stroma 
of Hepatocellular Carcinoma tissues through the induction of CXC chemokines in epithelial 
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cells. The recruited peritumoral neutrophils were an important source of matrix 
metalloproteinase-9 (MMP-9), which in vitro stimulated proangiogenic activity in 
hepatoma cells. Accordingly, in vivo neutrophil depletion inhibited tumor angiogenesis and 
growth (Kuang et al., 2011). On the other hand, Th17-derived IL-17 can synergize with 
IFN-  to induce CXCL9 and CXCL10 production in tumor cells, thus favoring the 
recruitment of cytotoxic T cells (Wei et al., 2012). 
III. 1.2. B cells 
Beyond their classical antibody-production function, B cells work together with other 
cell types, mainly T cells, in a number of antibody-independent effects (Bao and Cao, 
2014). Indeed B and T cells co-localize in secondary lymphoid organs, where T cells 
modulate B cell functions, through the release of cytokines (e.g. IL-21) that promote B cell 
clonal expansion, Immunoglobulin (Ig) production and class switching (Bao and Cao, 
2014). In turn, B cells modulate T cell functions, through their antigen-presenting 
capability and providing co-stimulatory molecules necessary for T cell activation and 
proliferation (Bindea et al., 2013; Nelson, 2010). Depending on the type of response in 
which they are involved, B cells produce a wide spectrum of cytokines, which orientate the 
immune response (Bao and Cao, 2014). For instance, in presence of Th1-related stimuli, B 
cells produce IL-12 or IFN-γ, whereas in a Th2 setting they produce IL-4 and IL-13 (Harris 
et al., 2000; Lund and Randall, 2010). In the skin, squamous carcinogenesis is limited in the 
absence of B cells (Andreu et al., 2010; Schioppa et al., 2011). Two mechanisms are 
responsible for the B cell-dependent skin carcinogenesis. Firstly, an increased deposition of 
IgG and Immunocomplexes (IC) within the tumor activates the Fc  receptors on myeloid 
cells (e.g. mast cells and macrophages), favoring angiogenesis and immunosuppression 
(Andreu et al., 2010; de Visser et al., 2005). Moreover, B cells produce IL-10 in a TNF- -
dependent manner, which in turn impaired anti-tumor IFN-  CD8
+
 T cell activity (Schioppa 
et al., 2011). In addition, in a transgenic murine model of cutaneous squamous cell 
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carcinoma, B cell depletion therapy improved platinum or paclitaxel based chemotherapy 
response. This effect was due to a macrophage “reprogramming” characterized by the 
increased production of CCR5-ligands responsible for the enhancement of CD8
+
 T cells 
recruitment (Affara et al., 2014). Moreover, in a murine model of prostate cancer, B cell 
derived lymphotoxin  activated the IκB kinase IKKα and STAT3 in cancer cells to 
enhance androgen refractory tumor growth and metastatic progression in a cell 
autonomous, NF- B independent mechanism (Ammirante et al., 2010). However, 
leukocyte pro-tumorigenic activities depend on tissue-specific signals, as highlighted by the 
fact that, in contrast to skin and prostate cancers, B cells lack of functional significance 
during mammary carcinogenesis (DeNardo et al., 2009). 
III.2. Innate Immune cells 
III. 2.1. NK cells 
NK cells are a family of innate immune cells, which play a central role in tumor 
immunosurveillance along with T cells (Pardoll, 2003). NK cells have the capacity to 
recognize infected or transformed cells and kill them. They are an important source of IFN-
, a potent immunostimulatory cytokine, which enhance antigen presentation and Th1 
responses (Koch et al., 2009). Unlike T cells, NK cells do not express restricted receptors 
(such as TCR), but two alternative classes of receptors. The first type is an inhibitory 
receptor, called “killer cell immunoglobulin like receptor” (KIRs), which binds MHC-I. 
When NK cells encounter normal MHC-I expressing cells, KIRs mediate the inactivation of 
the NK, keeping them in resting condition and preventing reactions against self (Vivier et 
al., 2012). When a cell down-regulates its MHC-I expression, the NK cell is activated 
(Moretta et al., 1997). As a mechanism of immunoescape, tumor cells can down-regulate 
MHC-I expression to evade CD8
+
 T cell recognition (Ferrone and Marincola, 1995). 
Therefore, NK cells can recognize the transformed cells and eliminate them (Ljunggren and 
Karre, 1990). The second class of receptors activates NK cells and is named NKG2D 
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(Natural Killer group 2, member D). These receptors bind a class of stress-induced ligands, 
such as MHCI polypeptide A (MICA) and B (MICB), and activate NK cells in presence of 
IL-15 or IL-2 (Nausch and Cerwenka, 2008). Under stress condition, tumor cells can 
express MICA or MICB and can easily activate NK cells (Carbone et al., 2005). Because of 
their crucial role in combating tumor cells, NK cells have been considered a promising tool 
for anticancer therapy. For instance, autologous NK-cell transfer has been experimented for 
the treatment of renal cell carcinoma, malignant glioma and metastatic breast cancer. 
However, the inhibition of NK cells by self MHC-I expressed by tumor cells significantly 
limited the efficacy of this approach. Subsequently, allogeneic NK transplantation 
efficiently prevented relapse, graft reaction and Graft versus Host disease (GvHD) in 
myeloid leukemia patients (Moretta et al., 2011; Ruggeri et al., 2002). Later, adoptive 
cellular transfer of allogeneic NK cells was also attempted for solid tumors such as 
neuroblastoma and ovarian cancer (Castriconi et al., 2004; Miller et al., 2005). Quite 
recently in patients with HCC treated by surgical resection, radiofrequency ablation, or 
percutaneous ethanol injections of activated cytokine-induced killer cells (CD3
+
/CD56
+
 and 
CD3
+
/CD56
–
 T cells and CD3
–
/CD56
+
 natural killer cells) significantly prolonged 
recurrence-free survival (Lee et al., 2015). 
III. 2. 2. Dendritic Cells (DC) 
Dendritic cells are a subset of myeloid cells, which play essential roles in activating 
adaptive immunity (Gabrilovich et al., 2012). Considered at the crossroad between innate 
and adaptive immune responses, DC act as professional APC that recognize foreign 
antigens in peripheral tissues, process and present them to T cells (Ley, 2014). To activate 
T cells, DC have to display a mature phenotype, consisting in the expression of co-
stimulatory molecules (CD80/CD86) and appropriate cytokines. Indeed, whether immature 
DC interact with T cells, the last undergo anergy, since immature DC express low levels of 
co-stimulatory molecules, low levels of MHC class II and express immunoregulatory 
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molecules such as surface-bound TGF-  (Guerder et al., 2013). Moreover even mature DC 
can display a tolerogenic phenotype, characterized by the production of immunoregulatory 
molecules such as Arginase 1 (ARG1), indoleamine 2,3 dioxigenase (IDO), TGF-  and IL-
10 (Hurwitz and Watkins, 2012; Novitskiy et al., 2008). In tumor-bearing hosts, the 
maturation of DC can be impaired, thus favoring T cell suppression (Lee et al., 2003; 
Mitsuka et al., 2013). In the tumor microenvironment, the functions of mature DC can also 
be compromised. For instance, tumor-related hypoxia negatively affected the functions of 
DC, by inducing the production of VEGF, IDO and ARG1 (Mancino et al., 2008). 
Moreover, tumor-conditioned DC tend to preferentially promote the function of 
CD4
+
CD25
+
 Foxp3
+
 Treg (Gai et al., 2013). 
III. 2. 3. Macrophages  
Macrophages are the most represented leukocytes in the microenvironment of solid 
tumors. Classically viewed as terminally differentiated cells, they were thought to derive 
from circulating monocytes and to differentiate at sites of inflammation under the influence 
of distinct molecules, such as M-CSF or GM-CSF (Allavena et al., 2008). However, a 
recent line of evidence suggests the existence, at least in mice, of a self-renewing 
population of macrophages, independent on bone marrow-derived monocytes, able to 
locally proliferate in addition to differentiate (Davies et al., 2011; Jenkins et al., 2011; 
Robbins et al., 2013). To date, only few studies in atherosclerosis and cancer indicate that 
macrophage proliferation also exists in humans (Lutgens et al., 1999) (Campbell et al., 
2011).  
A number of evidence in the last 20 years highlighted the multifunctional properties of 
macrophages, which are actually considered highly plastic cells, able to modify their 
phenotype in response to microenvironmental signals (Galdiero et al., 2013b). Under the 
influence of mediators such as IFN-γ, alone or together with microbial stimuli such as LPS, 
macrophages undergo classical M1 polarization, characterized by an immunostimulatory 
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phenotype able to induce cytotoxic and Th1 responses. M1 macrophages produce 
significant amount of IL-12 and IL-23 as well as Th1-attracting chemokines (i.e. CXCL9 
and CXCL10) and high levels of reactive oxygen and nitrogen species. In contrast, they are 
scarce producers of the immunomodulatory cytokine IL-10. On the other hand, IL-4 or IL-
13 are able to induce alternative M2 macrophages, characterized by a high production of 
chemokines such as CCL17, CCL22 or CCL24, involved in the recruitment of Th2 cells, 
Tregs, eosinophils and basophils, as well as a high production of IL-10. In contrast, M2 
macrophages produce low levels of IL-12 or IL-23 and are mainly involved in 
immunoregulatory networks, regulating tissue remodeling and angiogenesis (Mantovani et 
al., 2013) (Figure 4). 
M1 macrophages are responsible for resistance against intracellular pathogens such as 
Listeria monocytogenes, Salmonella typhi, Salmonella typhimurium and Mycobacterium 
species (Cavaillon and Adib-Conquy, 2006; Chacon-Salinas et al., 2005; Jouanguy et al., 
1999; Shaughnessy and Swanson, 2007). Moreover, M1 inflammation can lead to 
pathologic consequences. Indeed, during acute Escherichia coli or Streptococcus sp. 
infections, uncontrolled M1 inflammation is associated with gastroenteritis, urinary tract 
infections, neonatal meningitis and sepsis (Cavaillon and Adib-Conquy, 2006). M1 to M2 
switch is important in containing the inflammatory reaction, limiting tissue damage, such as 
during the respiratory syncytial virus-induced (RSV-induced) bronchiolitis (Shirey et al., 
2010). Failure to switch from an M1 to an M2 phenotype can lead to unresolved chronic 
inflammation, such as in chronic venous ulcers in humans (Sindrilaru et al., 2011). 
Macrophage activation has also been found in autoimmune diseases, such as systemic lupus 
erythematous (SLE) and rheumatoid arthritis (RA) (Haringman et al., 2005; Zhang et al., 
2010). In contrast, M2 polarization is associated with experimental and human parasitic 
infections (Noel et al., 2004). 
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In cancer, due to their Th1-immunostimulatory profile, M1 macrophages have been 
described to play important anti-tumor roles. For instance, Th1-driven macrophage 
activation mediates elimination of senescent hepatocytes, responsible for carcinogenesis 
(Kang et al., 2011). In contrast, tumor progression has been associated to a switch from M1 
to M2 phenotype. Indeed, tumor-associated macrophages (TAM) have been described to 
express a number of M2-like properties (Figure 5). In particular they promote growth, 
invasive behavior and metastatic potential of several tumors, such as renal cancer (Daurkin 
et al., 2011), breast cancer (Movahedi et al., 2010), pancreatic cancer (Gocheva et al., 
2010), lung (Koukourakis et al., 1998) and cervical cancer (Schoppmann et al., 2002), and 
as described by in vivo and in vitro models (DeNardo et al., 2009; Joyce and Pollard, 2009; 
Vasiljeva et al., 2006). TAM express a number of pro-angiogenic factors (such as VEGF 
and TGF-β) and release immunosuppressive molecules (such as TGF-β and IDO), thus 
shifting the balance towards a pro-tumor microenvironment (Galdiero et al., 2013b). 
IV. THE NEUTROPHIL  
The existence of polymorphonuclear granulocytes was first described by Paul Ehrlich in 
1878 on the basis of their distinct nuclear morphology. He called these cells “cells with 
polymorphous nucleus” and in 1905 Elie Metchnikoff renamed the cells 
“polymorphonuclear leukocytes”. Paul Ehrlich also observed that granules from different 
cells displayed specific staining properties. He called “basophils” for their affinity for basic 
aniline dyes, “eosinophils” for their affinity for acid aniline dyes and “neutrophils” for their 
low affinity for both basic and acid aniline dyes (Borregaard and Cowland, 1997; 
Kaufmann, 2008). In the same period, Elie Metchnikoff elaborated the phagocytic theory, 
whereby circulating cells contributed to defense against infectious agents by killing 
invading pathogens. Metchnikoff described two types of phagocytes, namely microphages 
(smaller phagocytes with highly polymorphic and fragmented nuclei) and macrophages 
(large phagocytic cells with a non-polymorphic nucleus). He proposed that microphages 
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exerted their phagocytic role essentially in septicaemia and anthrax and macrophages in 
tuberculosis. Therefore, he attributed a major role to granulocytes in acute infections by 
extracellular bacteria and a pivotal role to macrophages in chronic infections by 
intracellular bacteria (Kaufmann, 2008). 
Since their discovery and characterization, neutrophils have been considered as the first 
line of defense against pathogens and their role in immunology and immunopathology 
limited to the early phases of inflammation and resistance against extracellular pathogens 
(Amulic et al., 2012; Borregaard, 2010; Jaillon et al., 2013). Indeed, neutrophils were 
characterized by limited lifespan, easy activation and proper role of pathogen elimination. 
Therefore, their role in orchestrating the various phases of inflammation and the immune 
response has long been neglected. However, in the last two decades several evidence have 
challenged this view, suggesting a number of new fascinating roles and novel functional 
aspects for these underestimated phagocytes, revealing highly versatile and sophisticated 
cells, whose functions go far beyond the elimination of microbes. The finding of a 
prolonged lifespan under some circumstances (such as inflammatory conditions) and the 
introduction of new techniques useful to obtain highly pure neutrophil preparations and to 
perform in vivo studies of neutrophils in tissues have shed new light on neutrophil functions 
(Jaillon et al., 2013). The improvement in purification techniques has significantly 
contributed to the characterization of cytokine expression pattern (Davey et al., 2011b; 
Tecchio et al., 2013). 
IV. 1. Granulopoiesis 
Neutrophil production is the main activity of the bone marrow, with 10
9
 neutrophils per 
kg of body weight produced every day (Mary, 1985). Under the influence of cytokines and 
growth factors, hematopoietic stem cells differentiate into myeloblasts, promyelocytes, 
myelocytes, metamyelocytes, band cells and finally granulocytes (Borregaard, 2010). In 
physiological conditions, only mature neutrophils leave the bone marrow, with CXCR4 
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playing a crucial role in modulating neutrophil homing or egression (Lapidot and Kollet, 
2002). Bone marrow hematopoietic stem cells express CXCR4, which binds 
CXCL12/SDF-1 expressed by stromal cells, particularly osteoblasts. CXCR4 mediates 
bone marrow retention of myeloid cells and its expression decreases progressively during 
myeloid maturation. In parallel, CXCR2 expression increases and mediates mature 
neutrophil bone marrow egression (Lapidot and Kollet, 2002). Indeed, CXCR2 deficiency 
results in a myelokathexis-like phenotype with a cell-intrinsic retention of neutrophils in the 
bone marrow. Under inflammatory conditions, however, such as murine models of 
inflammation-driven colon cancer, Granulocytic Myeloid Derived Suppressor Cells (G-
MDSC) accumulated in peripheral blood of CXCR2
-/-
 mice, even though the recruitment in 
the tumor and adjacent inflammatory mucosa was significantly impaired (Katoh et al., 
2013). CXCR4 and CXCR2 antagonistically regulate neutrophil release from the bone 
marrow, but CXCR4 plays a dominant role. Indeed, in absence of CXCR4, CXCR2 signals 
are not required for neutrophil mobilization. Osteoblasts and endothelial cells both express 
CXCL12 and CXCR2 ligands (CXCL1 and CXCL2). However, osteoblasts display a 
higher expression of CXCL12, whereas endothelial cells display a higher expression of 
CXCR2 ligands (CXCL1 and CXCL2). Thus, while endosteal osteoblasts produce CXCL12 
for neutrophil retention, endothelial-derived chemokines (CXCR2 ligands) induce 
neutrophil chemotaxis to the circulation.  
Granulocyte colony stimulating factor (G-CSF) is the main regulator of neutrophil 
production and differentiation. Bone marrow stromal cells of monocyte/macrophage 
lineage as well as vascular endothelial cells, fibroblasts and mesothelial cells, produce G-
CSF. Upon binding to its receptor, G-CSF induces proliferation, differentiation and 
activation of granulocyte precursors (Demetri and Griffin, 1991). G-CSF is crucial during 
infections, but it is not absolutely required for granulocytopoiesis because G-CSF
-/-
 mice, 
even though neutropenic, still display residual granulocytopoiesis and produce fully mature 
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neutrophils, (Lieschke et al., 1994). In stress conditions, maximal blood neutrophil 
responses to G-CSF require CXCR2 signaling. Indeed, G-CSF administration was 
associated with marked suppression of endosteal osteoblast functions and increased CXCL2 
expression by bone marrow endothelial cells. Thus, a shift in the bone marrow balance 
from pro-retention (CXCL12) to mobilizing (CXCL1 and CXCL2) chemokines contributes 
to neutrophil mobilization by G-CSF (Eash et al., 2010).   
The production of neutrophils in the bone marrow is a tightly regulated process, resumed 
in a so-called “neutrostat regulatory loop” (Ley et al., 2006; Stark et al., 2005). The rate of 
apoptosis of peripheral neutrophils is an important regulator of myelopoiesis. Under 
homeostatic conditions, bone marrow neutrophil production strictly balances neutrophil 
peripheral elimination, thus keeping the stable level of circulating neutrophils (Stark et al., 
2005). Neutrophil turnover can be delayed or accelerated during inflammatory response, 
suggesting that modulation of neutrophil lifespan is important in determining whether an 
inflammatory response needs to be extended or terminated (Colotta et al., 1992). Under 
inflammatory conditions, in gut-associated lymphatic tissue, macrophages and DC produce 
IL-23. IL-23 stimulates IL-17A production by Th17 cells, which in turn stimulates G-CSF 
production in BM stromal cells, thus leading to enhanced granulocytopoiesis (Stark et al., 
2005). When efficient neutrophils carry out their functions in target tissues, they undergo 
apoptosis and are phagocytosed by macrophages and DC. This process reduces IL-23 
production by myeloid cells, completing the finely tuned loop feedback that regulates 
granulocytopoiesis (Stark et al., 2005).  
Recent elegant in vivo studies also describe that a circadian rhythm was involved in the 
patrol of circulating neutrophil number. This mechanism was related to a feedback circuit 
that involves selectins, chemokine receptors and β2-integrins. As circulating neutrophils 
age, they undergo down-regulation of L-selectin (CD62L), up-regulation of CXCR4 and 
CD11b and nuclear hypersegmentation. CD62L
low
CXCR4
high 
neutrophils return to the bone 
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marrow, where local macrophages ingest them. Phagocytosis of aged neutrophils by BM-
associated macrophages decreases the production of CXCL12 in macrophages, favoring the 
release of CD62
high
CXCR4
low
 neutrophils from the BM to circulation (Casanova-Acebes et 
al., 2013). This circadian fluctuation of neutrophil trafficking is likely due to signals 
derived from light cycle and transmitted through the nervous system. During the period of 
activity, sympathetic nerves induce expression of ICAM-1 and CCL2 in peripheral tissues 
endothelial cell together with the expression of V-CAM and CXCL12 in bone marrow 
(Scheiermann et al., 2012). These signals give rise to the peak of the peripheral tissue and 
bone marrow recruitment, with the lowest leukocyte counts in the peripheral blood (Lucas 
et al., 2008). 
IV. 2. Neutrophil granules and related proteins 
Neutrophil granules were first named “specific” to be distinguished from artifacts with a 
granular aspect. Subsequently two types of granules were distinguished on the basis of their 
affinity for dyes: azurophil granules, named for their affinity for the basic dye azure A, and 
specific granules, without affinity for this dye. The peroxidase staining method for electron 
microscopy revealed that myeloperoxidase was expressed only in azurophil granules. This 
technique allowed the distinction between the two subsets of granules: specific granules 
were considered as secretory granules, with important functions in modulating the 
inflammatory response, whereas azurophil granules were often considered as lysosomes, 
with a prevalent role in phagocytosis (Baggiolini, 1972; Gallin et al., 1984). This simplistic 
view was challenged when a tertiary type of granule formed in the late stages of 
granulopoiesis was revealed by electron microscopy (Spicer and Hardin, 1969).  
Granulopoiesis occurs during neutrophil maturation and granule appearance defines the 
transition from myeloblast to promyelocyte. The formation of granules continues until the 
segmented stage of maturation. During granulopoiesis, distinct proteins are synthesized and 
stored in distinct granules, which are actually classified in three subsets: primary 
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(azurophil), secondary (specific) and tertiary (gelatinase) granules (Figure 6). Primary 
granules are formed during the promyelocyte stage and are characterized by the presence of 
myeloperoxidase (MPO). Secondary granules are formed during the myeloblast stage and 
are characterized by the presence of lactoferrin and the pattern recognition molecule 
pentraxin-3 (PTX3). Tertiary granules are formed during the metamyelocyte/band cell stage 
and are characterized by the presence of gelatinase. Based on the “targeting by timing 
hypothesis”, granule proteins that are synthesized during the formation of particular 
granules are stored in these granules. Thus, granules formed at different stages during 
maturation display a different set of proteins (Borregaard, 2010). This distinction is 
operative because it not only reflects differences in content of granules but also differences 
in their mobilization with the granules formed latest being the first ones to be released 
(Borregaard and Cowland, 1997). During the last 25 years, high-resolution subcellular 
fractionation techniques, immune-electron microscopy and flow cytometry have shown a 
wide heterogeneity of neutrophil granules, allowing to identify an additional regulated 
exocytotic storage organelle, the secretory vesicles (Borregaard et al., 1990; Borregaard et 
al., 1992). Secretory vesicles consist in cytosolic organelles of membrane proteins 
containing a set of plasma proteins (Borregaard et al., 1992). They are generated by 
endocytosis during the last stage of granulopoiesis and upon neutrophil activation fuse their 
membrane with cell plasma membrane (Borregaard et al., 1987) (Sengelov et al., 1995). 
Granules and secretory vesicles do not have to be considered just storage organelles of 
proteolytic or bactericidal proteins retained until released. Indeed, they also contain 
membrane proteins, which are expressed on neutrophil surface upon the fusion of the 
secretory vesicle membrane to the neutrophil cellular membrane, during degranulation. In 
this way, neutrophil granules and secretory vesicles modify the ability of neutrophils to 
respond to the signals derived from the microenvironment (Borregaard and Cowland, 
1997). 
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IV. 3. Neutrophil recruitment 
The sequential process by which neutrophils leave circulation and migrate to tissues is 
defined as “neutrophil recruitment cascade”, and comprises five steps: tethering, rolling, 
adhesion, crawling and transmigration (Ley et al., 2007; Muller, 2013).  
In the first phases of the inflammatory response, inflammatory stimuli activate 
endothelial cells, which up-regulate P- and E- selectins on their surface. Neutrophils 
constitutively express selectin ligands, such as P-selectin glycoprotein ligand 1 (PSGL-1), 
which engage P- and E-selectins on endothelial cells and give rise to the tethering of 
neutrophils on the surface of the vessel wall. Tethering is followed by the rolling of 
neutrophils along the vessel in the direction of the blood flow. The engagement of PSGL-1 
on neutrophils also activates intracellular signals leading to neutrophil activation and firm 
adhesion (Wang and Arase, 2014; Yago et al., 2010). Indeed, during the rolling phase, 
chemokines lead to the β2-integrin clustering on neutrophils, enhancing their binding to the 
ligand Intracellular Adhesion Molecule- 1 (ICAM-1) expressed on activated endothelium 
and leading to firm adhesion of neutrophils to the endothelium. During early stages of 
inflammation, neutrophils extend a PSGL-1-rich microdomain into the vessel lumen that 
scans for activated platelets in the bloodstream. The intact distribution and signaling 
through PSGL-1 regulate neutrophil crawling, at least in part, orchestrating the appropriate 
distribution of the adhesive and chemotactic receptors CD11b/CD18 (Mac-1) and CXCR2. 
Only when productive interactions occur with platelets, neutrophils organize these 
additional receptors needed for intravascular migration or generate NETs, resulting in 
inflammation (Sreeramkumar et al., 2014). After adhesion, neutrophils cross the 
endothelium to gain the underlying tissue. Usually this process occurs in the endothelial 
cell junctions, through a mechanism involving cell adhesion molecules (Woodfin et al., 
2009). As an alternative way and in conditions of high ICAM-1 expression, neutrophils can 
migrate through pores in the cytoplasm of endothelial cells (transcellular migration) (Yang 
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et al., 2005). Beyond this generally accepted view, neutrophil recruitment mechanisms also 
display some variations in distinct organs. For instance, in the liver, neutrophils directly 
adhere to the activated endothelium, skipping the rolling step. Moreover, in sterile 
conditions neutrophil adhesion is ICAM-1-dependent, but during infections it occurs 
through hyaluronan – CD44 interactions between endothelial cells and neutrophils 
(McDonald and Kubes, 2012; McDonald et al., 2008).  
IV. 4. Neutrophil activation at sites of inflammation: beyond ROS and proteases 
Neutrophil behavior following transendothelial migration is dictated by the 
microenvironment, in particular by local chemokines and inflammatory factors, such as 
CXCL8 and TNF- . These molecules activate a number of downstream signals that finally 
lead to neutrophil activation and respiratory burst. It is important to take in mind that 
activation of Pattern Recognition Receptors (PRRs), such as Toll-Like Receptors, can also 
directly activate the oxidative burst (Hayashi et al., 2003; Trinchieri and Sher, 2007). 
Indeed, human neutrophils express all the known TLR, with the exception of TLR3. The 
activation of TLRs induced cytokines release, superoxide generation, L-selectin shedding 
while inhibited chemotaxis to CXCL8 and increased phagocytosis (Hayashi et al., 2003). A 
number of mechanisms are used by neutrophils to kill pathogens, including phagocytosis, 
antimicrobial peptides and the release of Reactive Oxygen Species (ROS) during 
respiratory burst (Borregaard et al., 2007).  
However, during the last 10 years, neutrophils were found to display an antimicrobial 
armamentarium far beyond ROS and antimicrobial peptides. For instance, neutrophils 
extrude an extracellular fibrillary network, called Neutrophil Extracellular Traps (NETs) 
composed of nuclear elements (DNA and histones) together with proteins from primary 
(e.g. MPO and elastase (Brinkmann et al., 2004), secondary (e.g. lactoferrin and PTX3) 
(Jaillon et al., 2007) and tertiary granules (e.g. MMP-9) (Brinkmann et al., 2004). A study 
has identified by mass spectrometry 24 neutrophil NET-associated proteins (Urban et al., 
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2009). Among them are a number of antimicrobial proteins, such as histones, defensins, 
elastase, cathepsin G and MPO (Urban et al., 2009) and also the pattern recognition 
molecule PTX3 (Jaillon et al., 2007). Recently, mitochondrial DNA was also found in 
NETs suggesting a role for mitochondria in NETs formation (Yousefi et al., 2009). These 
web-like structures have the capacity to trap different types of microbes (e.g. Escherichia 
coli, Shighella flexeneri, Staphylococcus aureus), fungi (e.g. Candida albicans, 
Asperigillus fumigatus) and human immunodeficiency virus-1 (HIV-1), supporting their 
interaction with effector molecules and their clearance (Brinkmann and Zychlinsky, 2012; 
Saitoh et al., 2012; Yousefi et al., 2009). For instance, the antimicrobial heterodimer 
calprotectin released in NETs plays a key role in defense against Candida albicans and 
Aspergillus fumigatus (McCormick et al., 2010). 
The process of NET formation is an alternative type of death, distinct from necrosis or 
apoptosis and is called NETosis (Fuchs et al., 2007). NETs formation is a complex 
mechanism involving specific molecular pathways and morphological changes and it is not 
completely understood. NETosis requires chromatin decondensation, which involves the 
generation of ROS, the translocation of neutrophil elastase (NE) from granules to nucleus, 
the citrullination of histones by Peptidylarginine Deaminase 4 (PAD4) and the induction of 
neutrophil autophagy (Wang and Wang, 2013). Accordingly, PAD4 deficient mice are not 
able to form NETs and display a significantly impaired antimicrobial activity (Loges et al., 
2010). NET formation is also related to oxygen peroxide produced by NADPH oxidase, 
further converted by MPO. Indeed, neutrophils deficient in MPO or NAPDH (such as in 
Chronic Granulomatous Disease - CGD - patients) display reduced NET production, likely 
responsible for the higher susceptibility to infections observed in CGD (Bianchi et al., 
2009; Metzler et al., 2011).  
The NETosis process is tightly regulated. Indeed, the activation of this process relies on 
the competition of two cellular processes for neutrophil elastase (NE): phagolysosome 
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homing or nuclear translocation. Small microbes are taken up in the phagosome and 
activate phagocytosis. Phagocytosis involves the fusion of azurophilic granules to the 
phagosome, and therefore the sequestration of NE within the phagolysosome away from the 
nucleus. In contrast, when microbes are too large to be phagocytosed, NE is released from 
the azurophilic granules to the nucleus (Branzk et al., 2014). Once in the nucleus, NE 
cleaves histones, decondenses chromatin and drives NET formation (Papayannopoulos et 
al., 2010). According to these findings, the size of the microbes is the factor that determines 
the need of NET formation. Since a number of pathogens have evolved virulence strategies 
to circumvent phagocytosis, NET formation can also be viewed as an immune response to 
overcome these resistance strategies (Branzk et al., 2014).  
Microbes have developed a number of tools to escape NET trapping too and, then, to 
enhance their virulence. For example, Streptococcus pyogenes and Streptococcus 
pneumoniae express DNAse-1 which disrupt NETs (Beiter et al., 2006; Buchanan et al., 
2006). In addition, some strains of Pseudomonas aeruginosa have developed resistance to 
NET-mediated killing in fibrosis cystic patients airways (Young et al., 2011). Moreover, 
Leishmania donovani presents some cell wall structures (lipophosphoglycan) which confers 
resistance to NETs-mediated killing, even though neutrophil extracellular traps still 
contribute to the containment of the parasites (Gabriel et al., 2010). 
Similarly to other neutrophil related molecules, NETs can also be dangerous for the host. 
Excessive and deregulated NET formation is responsible for various pathologic conditions, 
such as autoimmunity, sepsis and thrombosis. For example, a subset of SLE patients has 
been identified with an impaired DNAse-1 activity. This defect was due to the presence of 
DNAse-1 inhibitors or to antibodies that bind to NETs and protect them from DNAse-1. In 
these patients, persistence of NETs, anti-NETs antibodies, anti-dsDNA titers and lupus 
nephritis were strongly correlated. It was proposed that anti-NETs antibodies and persistent 
NETs could form “NET immunocomplexes”, which are relevant in the exacerbation of SLE 
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and could be pathogenic in the development of lupus nephritis. (Hakkim et al., 2010). 
Indeed, clinically, flares of autoimmune diseases are often associated with bacterial 
infections and may reflect the consequences of acute activation of neutrophils and the 
generation of more NETs and antigens (Zandman-Goddard and Shoenfeld, 2005). In 
addition, NETs were recently shown to activate platelets and induce thrombosis. Indeed, 
NETs provide a scaffold for platelet and red blood cell adhesion and aggregation (Fuchs et 
al., 2010). In a murine model of deep venous thrombosis, neutrophils were necessaries for 
activation of factor XII and propagation of the thrombosis cascade (von Bruhl et al., 2012). 
In addition, NET components such as DNA, histones and proteases retain intrinsic pro-
coagulant activities. For instance, genomic DNA potentiated proteolytic activity of 
coagulation factors (Kannemeier et al., 2007). Moreover, histones contained in NETs are 
cytotoxic for endothelium and can be responsible for thrombosis in vivo, as observed in 
animal model of sepsis (Xu et al., 2009).  
IV. 5. Neutrophil-derived cytokines 
Neutrophils have also been reconsidered as a source of stored and newly synthesized 
cytokines. For instance, recent evidence demonstrated that murine neutrophils produce IL-
1β following LPS stimulation, in a NLRP3 inflammosome dependent manner (Mankan et 
al., 2012). Previous results indicated that human neutrophils were not able to activate the 
MyD88-independent/TRIF-dependent pathway upon TLR4 engagement and thereby failed 
to produce IFN-  following LPS stimulation (Tamassia et al., 2007). The same group 
subsequently found that DNA-transfected human neutrophils become able to produce IFN-
β following IRF3 activation because of the triggering of intracellular DNA sensors, 
highlighting the role of neutrophils in recognizing microbial cytosolic DNA (Tamassia et 
al., 2012). Moreover, neutrophils have been described to produce a number of other 
cytokines and chemokines, such as TNF-Related Apoptosis Inducing Ligand (TRAIL), 
CCL20, CXCL8, IL-1 Receptor Antagonist (IL-1Ra) and B cell Activating Factor (BAFF) 
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(Table 2). More in details, the two B-cell related cytokines BAFF and A Proliferation 
Inducing Ligand (APRIL) have been recently described as part of the neutrophil-derived 
cytokines, suggesting a central role for neutrophils in B cell mediated autoimmune or 
neoplastic diseases (Mantovani et al., 2011) (Puga et al., 2012). In addition, human and 
murine neutrophils have been described to express IL-17A in psoriasis and rheumatoid 
arthritis (Lin et al., 2011; Moran et al., 2011). However it is important to take in mind that 
murine and human neutrophils significantly differ each other. For instance, the production 
of IL-10 from human neutrophils has been a matter of debate. Indeed, murine neutrophils 
have been shown to produce IL-10 in several pathologic conditions, such as Candida or 
Staphylococcus aureus infections (Greenblatt et al., 2010; Zhang et al., 2009). In contrast, 
the finding of IL-10 production by human neutrophils following serum Amyloid A 
stimulation (De Santo et al., 2010) has not been confirmed by other groups, thus pointing to 
the need for a stringent neutrophil purification, devoid of any minimal monocyte 
contamination (Davey et al., 2011b; Tamassia et al., 2013). Furthermore, Tamassia and 
colleagues recently clarified this aspect showing that, unlike monocytes or the murine 
counterpart, human neutrophils could not switch on the IL-10 gene because of the inactive 
state of the locus (Tamassia et al., 2013). 
IV. 6. Neutrophils as a source of Pattern Recognition Molecules (PRMs) 
In addition to be a reservoir of proteolytic and antimicrobial molecules and to express a 
set of cytokines and chemokines, neutrophils have also been found to be a source of pattern 
recognition molecules (PRMs). These membrane-bound or soluble molecules retain the 
capability to identify pathogen associated molecular patterns (PAMPs), to discriminate self 
versus non-self and to initiate a coordinated immune response (Jaillon et al., 2013). 
PRMs expressed by neutrophils include all the known TLRs excepted TLR3 (Hayashi et 
al., 2003), the C-type lectin receptors Dectin-1, Mincle, CLEC2 and CLECSF8 (Graham et 
al., 2012; Kennedy et al., 2007; Kerrigan et al., 2009; Lee et al., 2012) and a number of 
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cytosolic DNA sensors, such as MDA5, STING and RIG1 (Tamassia et al., 2012; Tamassia 
et al., 2008). Dectin-1, the main -glucan receptor, plays a major role in defense against 
fungi such as Candida albicans and Aspergillus fumigatus (Kennedy et al., 2007). 
Cytosolic DNA sensors recognize microbial nucleic acids and activate the expression of 
IFN- , thus playing important roles in defense against intracellular pathogens such as 
Listeria monocytogenes, Legionella pneumophila and adenovirus (Tamassia et al., 2012). 
Neutrophils also express the Formyl Peptides Receptors 1 (high-affinity) and 2 (low-
affinity), which recognize bacterial and mitochondrial formyl peptides. Once activated, 
these receptors mediate neutrophil activation and migration through p38 or Erk activation 
respectively (Liu et al., 2012; McDonald et al., 2010). 
Neutrophils also display a number of soluble PRMs, stored in granules and released upon 
activation. These molecules are part of the humoral arm of innate immunity, share similar 
functions with the antibodies and include PTX3, proteoglycan recognition receptor (PGRP-
S) and M-ficolin. 
PTX3, a member of the long pentraxin family, is stored in secondary granules of 
neutrophils in a ready to use form and is rapidly mobilized upon neutrophil activation. 
PTX3 has been reported to be associated with NETs (Jaillon et al., 2007). PTX3 acts as an 
opsonin against Aspergillus fumigatus and Pseudomonas aeruginosa. Following 
opsonisation, PTX3 activates phagocytes through Fc RIIA engagement and amplifies C3b-
opsonized pathogen phagocytosis (Moalli et al., 2010; Moalli et al., 2011). Interestingly, 
PTX3 acts also as a regulator of neutrophil recruitment and activation. Indeed, PTX3 
attenuated neutrophil recruitment at sites of inflammation, through the interaction with P-
selectin (Deban et al., 2010) and translocated from granules to membrane of apoptotic 
neutrophils to favor their recognition and clearance by macrophages (Jaillon et al., 2009). 
In addition, PTX3 has recently emerged as key regulator of complement cascade in 
modulating cancer susceptibility in mice and humans. Indeed, in murine models of 
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carcinogen-induced tumors, lack of PTX3 was associated with increased cancer 
susceptibility, due to a deregulated complement activation and increased macrophage M2-
polarization (Bonavita et al., 2015). 
PGRP-S and M-ficolin are stored in secondary and tertiary granules (Cho et al., 2005; 
Rorvig et al., 2009). As the main proteoglycan receptor, PGRP-S plays major roles in 
defense against microbes such as Staphylococcus aureus and Bacillus subtilis, exerting 
batteriostatic and battericidal functions (Cho et al., 2005; Kashyap et al., 2011). M-ficolin is 
a member of the lectin family, activates complement cascade, acts as an opsonin and plays 
important roles in defense against Gram-positive and Gram-negative bacteria. Neutrophil-
derived M-ficolin is also able to activate neutrophils themselves through the interaction 
with the surface molecule CD43 (Moreno-Amaral et al., 2012; Rorvig et al., 2009). 
IV. 7. Neutrophils in immune cell cross-talk 
Given their complex and multi-faced functions, neutrophils can be part of a dynamic 
interplay with innate immune cells, such as DC, monocytes, macrophages and NK cells, 
and adaptive immune cells, such as T and B cells. By establishing these interactions, 
neutrophils receive and integrate signals modulating their activation and survival and, on 
the other hand, modulate effector immune responses.  
IV. 7. 1. Neutrophils and innate immune cells 
Activated neutrophils were shown to promote maturation of human monocyte-derived 
DC (mo-DC), through interaction between CD18 and CEACAM-1 (carcinoembryonic 
antigen-related cell adhesion molecule-1) expressed by neutrophils and DC-SIGN (DC-
specific ICAM3-grabbing non-integrin) on mo-DC (Schuster et al., 2013). In mice, 
neutrophils are also able to induce maturation of bone marrow-derived DC, through the 
production of TNF-  (van Gisbergen et al., 2005a; van Gisbergen et al., 2005b). Mo-DC 
maturated in the presence of neutrophils acquire the potential to induce T cell proliferation 
and polarization towards Th1 phenotype (Megiovanni et al., 2006). Supernatants from 
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parasite-infected neutrophils induced IL-12 and TNF-  production and CD40 and CD86 
up-regulation in DC, in a TNF-  dependent manner. Splenic DC from neutrophil-depleted 
mice showed a significantly lower IL-12 and TNF-alpha production, thus confirming the 
pivotal role exerted by neutrophils in microbial-triggered DC maturation (Bennouna et al., 
2003). 
In contrast, neutrophils can also negatively affect DC maturation and functions. For 
instance, neutrophil elastase significantly impaired the DC allostimulatory ability switching 
them into TGF- 1-secreting cells (Maffia et al., 2007). Accordingly, neutrophil-derived 
extracellular vesicles (or ectosomes) modified mo-DC morphology, reduced their 
phagocytic activity, and increased the release of TGF- 1. Even under LPS stimulation, the 
DC maturation process was partially inhibited as suggested by reduced expression of cell 
surface markers (i.e. CD40, CD80, CD83, CD86), inhibition of cytokine-release (IL-8, IL-
10, IL-12, and TNF- ), and reduced capacity to induce T cell proliferation (Eken et al., 
2008). 
Neutrophils can modulate cytokine production and microbicidal activity of macrophages. 
For instance, apoptotic neutrophils further enhanced macrophage proinflammatory 
properties following Mycobacterium tuberculosis infection, through the activation of the 
NLRP3 inflammasome and IL-1β signaling (Andersson et al., 2014). During 
Mycobacterium tuberculosis infection, close interactions between macrophages and 
neutrophils were observed. Indeed, macrophages phagocytosed NETs and produced IL-6, 
TNF-α, IL-1β and IL-10 when co-cultured in presence of NETs from Mtb-activated 
neutrophils (Braian et al., 2013). In contrast, apoptotic neutrophil phagocytosis can also 
induce an IL-10
high
 IL-12
low 
immunomodulatory phenotype in macrophages, favoring tissue 
repair and return to homeostasis (Filardy et al., 2010). 
Neutrophils also participate in an important bidirectional cross-talk with NK cells. On the 
one hand, NK-derived soluble factors, such as IFN-  and GM-CSF significantly improve 
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neutrophil life span and ROS production (Bhatnagar et al., 2010; Costantini and Cassatella, 
2011). On the other hand, neutrophils are required for NK maturation and activation. 
Indeed, in a murine model of genetically induced neutropenia, poor survival, hyporeactivity 
and impaired development of NK were observed (Jaeger et al., 2012; Ordonez-Rueda et al., 
2012). Similar defects in maturation and activation of NK were also described in patients 
suffering from cyclic neutropenia, suggesting that neutrophil-NK interaction is important 
also in humans (Jaeger et al., 2012).  
Interestingly, a peculiar “ménage a trois” has been described between neutrophils, NK 
cells and a specific myeloid DC subset, namely 6-sulfo-LacNAc myeloid DC (slanDC). 
Indeed, neutrophils induced the release of IL-12p70 by slanDC via the interaction between 
CD18 and ICAM-1. SlanDC-derived IL-12p70 stimulated NK cells to produce IFN- , 
which in turn further enhanced neutrophil-induced IL-12p70 production in SlanDC, thus 
fueling a peculiar positive feedback loop (Costantini et al., 2011). Neutrophils and NK cells 
can also negatively influence each other. For instance, neutrophil-derived microparticles 
(ectosomes) inhibited the production of IFN-γ and TNF-α but enhanced the release of TGF-
β1 by IL-2/IL-12-activated NK cells, switching NK from an immunostimulatory to an 
immunomodulatory phenotype (Pliyev et al., 2014). In contrast, NK cells can induce 
neutrophil apoptosis in a contact-dependent manner through the interaction between NKp46 
and Fas (Thoren et al., 2012). 
Even though quite neglected, the interaction between neutrophils and invariant NKT cells 
(iNKT) also plays a role in modulating inflammatory reactions. For instance, a cell-cell 
contact between these cells has been described in vitro, leading to iNKT function 
impairment. Accordingly, during neutrophil-mediated inflammatory reactions, cytokine 
production and activation of iNKT cells were significantly reduced (Wingender et al., 
2012). 
IV. 7. 2. Neutrophils and adaptive immune cells 
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Neutrophils also communicate with adaptive immune cells, such as T lymphocytes. 
Indeed, neutrophils induce Th1 and Th17 cells migration through the release of CXCL10 or 
CCL20, respectively. Association between neutrophils and Th17 cells was observed in 
colonic mucosa of Crohn’s patients and in the synovial fluid from rheumatoid arthritis 
patients (Pelletier et al., 2010a). In addition, Th17 and Tregs are able to release CXCL8, 
and activated T cells are able to modulate neutrophil survival and activation through the 
production of GM-CSF, IFN-  or TNF-  (Davey et al., 2011a; Himmel et al., 2011; 
Pelletier et al., 2010b). Moreover, neutrophils migrate to the lymph nodes in a CCR7-
dependent manner and can exert APC functions. Indeed, neutrophils were able to recognize 
and process the antigen in MHC-I context, present it to CD8+ T cells through a process of 
cross-presentation and prime CD8 T cells to become cytotoxic effector cells (Abi Abdallah 
et al., 2011; Beauvillain et al., 2011; Beauvillain et al., 2007). 
Neutrophils interact with B cells, influencing several aspects of B cell functions. Indeed, 
a specific neutrophil population colonizing the peri-marginal zone of the spleen was 
identified, named “B-helper neutrophils” (NBH). Compared to circulating neutrophils, these 
cells displayed a high expression of B-cell supporting molecules such as BAFF, APRIL, 
IL-21 and CD40L, as well as B-cell attracting chemokines such as CXCL12 and CXCL13. 
B helper neutrophils formed B cell-interacting NETs-like structures and favored 
Immunoglobulin (Ig) class switch and somatic hypermutations. Patients with genetically 
induced neutropenia also displayed a reduction in T-independent antigen specific Igs, 
whereas T-dependent antigen Ig production was intact. These data supported the role of 
neutrophils in creating an innate antibody-mediated antimicrobial humoral defense through 
their direct interaction with B cells also in humans (Puga et al., 2012). 
IV. 8. Neutrophils in the resolution of inflammation 
Neutrophils content is deleterious for microbes but also, potentially, for the host. 
Therefore, the clearance of recruited neutrophils at sites of inflammation is an important 
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phase of the resolution of inflammation (Buckley et al., 2013). Failure of neutrophils to 
undergo apoptosis or failure of macrophage to eliminate apoptotic neutrophils can lead to 
prolonged and deregulated inflammation. Apoptotic neutrophils undergo several 
modifications, including alterations of cell surface markers (e.g. increased expression of 
phosphatidylserine) and membrane relocalization of intracellular components (e.g. PTX3, 
endoplasmic reticulum proteins and nucleosomes) that promote their clearance by 
phagocytes, such as macrophages (Fox et al., 2010; Jaillon et al., 2009) (Soehnlein and 
Lindbom, 2010). Within the inflammatory microenvironment neutrophil clearance is 
modulated by a number of factors, such as IL-1β, G-CSF and GM-CSF as well as hypoxia 
that delay neutrophil apoptosis (Thompson et al., 2014; Witko-Sarsat et al., 2010) or TNF-
α, which can both accelerate apoptosis or enhance neutrophil survival in a concentration-
dependent manner (Cross et al., 2008). As a mechanism aimed at limiting the inflammatory 
response, during apoptosis neutrophils release soluble factors, such as lactoferrin or 
annexin A1, which reduce the recruitment of inflammatory cells (Perretti and D'Acquisto, 
2009) (Bournazou et al., 2009). Moreover, apoptotic neutrophils and macrophages 
following phagocytosis of apoptotic neutrophils increase the production of lipid pro-
resolving mediators, such as lipoxins, resolvins and protectins (Dalli and Serhan, 2012; 
Serhan et al., 2008). Indeed, in the latest stages of the inflammatory cascade, neutrophils 
switch the eicosanoid biosynthesis from Leukotriene B4 to Lipoxin A4, thus limiting 
further neutrophil infiltration. Lipoxin A4 acts on its specific G-protein coupled receptor 
(GPCR) expressed on neutrophils, modifies the phosphorylation state of cytoskeleton 
proteins and causes cell arrest (Serhan et al., 2008). In addition, Lipoxin A4 prevents 
neutrophil L-selectin shedding and integrin up-regulation (Filep et al., 1999). Also 
neutrophil derived resolvins limit neutrophil infiltration, as demonstrated in a number of in 
vivo models (Chiang et al., 2012; Krishnamoorthy et al., 2010; Serhan et al., 2008; Spite et 
al., 2009). The two members of this family RvD1 and RvE2 directly interact with specific 
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GPCRs, and RvE2 interact with LTB4 receptor, limiting neutrophil chemotaxis (Arita et al., 
2007; Serhan et al., 2008). In addition, they also impair neutrophil adhesion to the 
endothelium by modulating neutrophil integrin expression and CD62L shedding 
(Krishnamoorthy et al., 2010; Spite et al., 2009). In addition, resolvins up-regulate CCR5 
expression on apoptotic neutrophils, enhancing the clearance of chemokines such as CCL3 
and CCL5 (Ariel et al., 2006). Also live neutrophils retain the ability to capture and entrap 
chemokines and cytokines, thus limiting their effects. For instance, neutrophils express IL-
1Ra, which engages IL-1R without any signal transduction and the decoy IL-1R type II, 
which captures IL-1  preventing its interaction with the functional IL-1R1 (Bourke et al., 
2003; Cassatella et al., 1994). 
V. NEUTROPHILS IN DISEASES 
From the classical point of view, neutrophils have long been studied as immune cells 
with a pivotal role in defense against pathogens. However, recent lines of evidence shed 
new light on neutrophils as key contributors of many diseases such as chronic inflammatory 
diseases, autoimmune diseases and cancer (Galdiero et al., 2013b; Jaillon et al., 2013). 
V. 1. Infections 
Traditionally, neutrophils have been considered crucial soldiers in the battle against 
extracellular pathogens. However, recent lines of evidence also suggest a role for 
neutrophils in combating intracellular microbes. For instance, a genome-wide 
transcriptional analysis of peripheral blood neutrophils purified from patients with active 
tuberculosis indicated a type I IFN-related signature, suggesting a role for these cells in the 
pathogenesis of M. Tuberculosis infection (Berry MP Nature 2010). In the same line of 
evidence, Tamassia and colleagues demonstrated the ability of neutrophils to produce IFN-
β upon infection by intracellular pathogens (e.g. L. pneumophila, L. monocytogenes) 
through the activation of cytosolic DNA sensors (Tamassia et al., 2012). Moreover, 
neutrophils express a functional and active TLR9 on their membrane surface. This receptor 
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was activated by oligonucleotides containing unmethylated CpG motifs, providing an 
additional tool to recognize microbial nucleic components when endosomes were not 
accessible to TLR9 ligands (Lindau et al., 2013). TLRs also act as modulators of neutrophil 
recruitment. Indeed, engagement of TLRs on neutrophils led to activation of G-coupled 
receptor kinase 2 and to desensitization and internalization of CXCR2, limiting neutrophil 
migration at sites of inflammation (Alves-Filho et al., 2009; Trevelin et al., 2012). 
Accordingly, in a murine model of sepsis, TLR9 deficiency was associated to enhanced 
neutrophil infiltration, lower inflammatory response and improved outcome (Trevelin et al., 
2012). In addition, the IL-1 family member IL-33 inhibited the down-regulation of CXCR2 
induced by TLR4 activation, thus increasing neutrophil recruitment and improving outcome 
in sepsis (Alves-Filho et al., 2010). Indeed, septic patients who did not survive displayed 
higher levels of soluble ST2, a circulating decoy receptor for IL-33, thus supporting the 
important role played by IL-33 in modulating neutrophil response and outcome of septic 
patients (Alves-Filho et al., 2010). In addition, in a murine model of C. Albicans infection, 
IL-33 promoted neutrophil recruitment at sites of infection through the enhanced CXCL1 
and CXCL2 production from macrophages and the inhibition of CXCR2 down-modulation 
on neutrophils. Moreover, IL-33 pretreatment enhanced neutrophil CR3 expression, 
through a synergism between TLR and dectin-1 pathways, resulting in improved 
phagocytosis and killing of the opsonized C. albicans (Alves-Filho et al., 2010; Le et al., 
2012).  
V. 2. Chronic inflammation and autoimmune diseases 
An uncontrolled neutrophil activation or impaired neutrophil clearance can be 
responsible for chronic inflammatory or autoimmune diseases, with dangerous 
consequences for the host. 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease and a major cause 
of morbidity and mortality in western countries. From the pathological point of view it is 
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characterized by a significant neutrophil infiltration, due to chemotactic stimuli such as 
CXCL8 and leukotriene B4 (LTB4). It has been shown that COPD patients display high 
levels of immunoglobulin-free light chains in serum and lungs, which activate neutrophils 
and induce the release of CXCL8, favoring a positive feedback loop which further 
promotes neutrophil infiltration in damaged lungs (Braber et al., 2012). In addition, LTB4 
is synthesized by Leukotriene A4 hydrolase (LTAH4), an enzyme that also retains an 
aminopeptidase activity, which is responsible for the catabolism of the tripeptide proline-
glycine-proline PGP, a potent neutrophil chemoattractant. Interestingly, cigarette smoke 
inhibits the aminopeptidase activity but not the hydrolase activity of the enzyme, increasing 
neutrophil recruitment and inflammation (Snelgrove et al., 2010). In contrast, chloride ions 
are able to activate the aminopeptidase activity of LTA4 hydrolase. However, in cystic 
fibrosis patients, due to the impaired functions of the cystic fibrosis transmembrane 
conductance regulator (CFTR), chloride ions extracellular levels are reduced, with 
consequent high levels of PGP and enhanced neutrophil pulmonary infiltration, which 
partially contributes to the emphysematous aspect of the lungs in these patients (Snelgrove 
et al., 2010). In addition, once recruited, neutrophils release high levels of gamma-
glutamyl-peptidase, an enzyme involved in the catabolism of glutathione, thus reducing the 
local levels of anti-oxidant and impairing the respiratory functions of cystic fibrosis patients 
(Corti et al., 2012). In addition, in a murine model of acute intestinal inflammation, 
transmigrating neutrophils modified the transcriptional profile of the epithelial cells. More 
in details, during the acute phase of inflammation, recruited neutrophils gave rise to the 
respiratory burst with consequent local oxygen depletion. Local hypoxia stabilized 
hypoxia-inducible factor (HIF1- ) in epithelial cells, which preserves mucosal barrier 
homeostasis, by increasing goblet cell number and mucus production (Campbell et al., 
2014). 
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Neutrophils play also important roles in pathogenesis of autoimmune diseases. Indeed, 
NETs are a source of self-antigens, such as nucleic acids and ribonucleoproteins in SLE, 
deaminated histones in Felty syndrome, proteinase 3 or MPO in Anti-neutrophil 
Cytoplasmic Autoantibody (ANCA)-associated vasculitis, citrullinated histones in RA 
(Khandpur et al., 2013; Radic and Marion, 2013).  
ANCA-related vasculitis is a subset of autoimmune diseases characterized by chronic 
inflammation of blood vessels. ANCAs are a class of autoantibodies mainly directed 
against the cytoplasmic neutrophil proteins MPO or proteinase 3. The mechanism by which 
intracellular neutrophil proteins become antigenic remains still a matter of debate, but a role 
for NETosis, responsible for the exposure of self-antigens to the immune response has been 
proposed. For instance, serum of SLE patients contains immune complexes composed of 
antibodies anti-ribonucleoproteins and antimicrobial peptides. Following exposure to SLE-
derived anti-ribonucleoprotein antibodies, neutrophils release NETs, which activate 
dendritic cells, in a TLR9-dependent manner. DC activation by NET-related 
immunocomplexes induces the release of IFNs by DC, which in turn activate neutrophils, 
and give rise to a positive feedback loop responsible for the chronic pathogenesis of the 
disease (Garcia-Romo et al., 2011; Lande et al., 2011). Moreover, NETs have been found in 
glomeruli and interstitium of kidney biopsies in vasculitis patients, supporting the role for 
NETs in tissue damage (Kessenbrock et al., 2009; Mulder et al., 1995). ANCAs directly 
activate neutrophils, leading to the release of ROS, proteases and cytokines, responsible of 
tissue damage. In addition, ANCAs activate the complement cascade, leading to the 
formation of C5a, a potent neutrophil chemoattractant, thus sustaining an autonomous loop 
that continuously fuels vascular inflammation (Schreiber et al., 2009). In vivo studies 
further support the central role of neutrophils in vasculitis pathogenesis, because 
neutrophil-depleted mice were protected from anti-MPO IgG-induced ANCA vasculitis 
(Mulder et al., 1995).  
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Rheumatoid arthritis (RA) is a chronic autoimmune polyarthritis and is characterized by 
neutrophil infiltration in the affected joints. Neutrophils play a pivotal role in tissue 
damage, through the release of ROS and proteases and recruit other immune cell 
populations through the release of chemokines, thus orchestrating the various phases of the 
inflammatory reaction (Wright et al., 2014). For instance, RA synovial fluid neutrophils 
produce high levels of the Receptor Activator of the Nuclear Factor k-B Ligand (RANKL) 
and BAFF, which activate osteoclasts and B cells, respectively (Assi et al., 2007; 
Chakravarti et al., 2009). Moreover, circulating immunocomplexes, which are typical of 
RA, activate synovial neutrophils via Fc Rs. Cross-linking of IgGs bound on neutrophils 
lead to degranulation, ROS release and enhancement of neutrophil adhesion to endothelial 
cells, thus amplifying tissue damage (Rollet-Labelle et al., 2013). Finally, NETs play also a 
central role in neutrophil-mediated RA pathogenesis. Indeed, peripheral blood and synovial 
fluid neutrophils from RA patients displayed an increased susceptibility to produce NETs in 
basal conditions. NETosis was mediated by circulating autoantibodies (Rheumatoid Factor 
and/or Anti-Citrullinated Peptides antibodies – ACPA) together with inflammatory 
cytokines such as TNF-  and IL-17A. During NETosis, neutrophils extrude citrullinated 
autoantigens, such as citrullinated vimentin, which in turn further enhance NET release. 
NETs also directly activate fibroblast-like synoviocytes to produce proinflammatory 
molecules such as IL-6 and IL-8 (Khandpur et al., 2013). 
Neutrophils have also been described to play important roles also in a murine model of 
multiple sclerosis and type I diabetes, mainly due to CXCR2-related mechanisms 
(Battaglia, 2014; Liu et al., 2010). 
V. 3. Cancer 
Among myeloid cells infiltrating the tumor stroma, tumor-associated macrophages 
(TAM) have been widely described as central cells orchestrating tumor growth, stroma 
remodeling, angiogenesis and T cell-dependent immunity (Balkwill et al., 2005; Biswas 
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and Mantovani, 2010; Pollard, 2004). Because of their short half-life and terminally 
differentiated phenotype, the role of neutrophils in tumor development has been considered 
negligible. However, new in vivo and in vitro techniques have completely changed this 
point of view and recent evidences suggest important roles of neutrophils in modulating 
tumor behavior. More in details Tumor-Associated Neutrophils (TAN) have been shown to 
exert anti-tumoral as well as pro-tumoral functions and findings derived from murine 
models suggest that neutrophils are endowed with unsuspected plasticity (Fridlender et al., 
2009; Mantovani, 2009). In the context of cancer related inflammation, neutrophils emerge 
as candidates that modulate all steps of cancer initiation and growth as well as antitumor 
immunity. 
V. 3. 1. Neutrophil occurrence in tumors and their prognostic significance 
Within the tumor microenvironment, tumor and stromal cells produce a number of CXC 
chemokines (CXCL8, CXCL1, CXCL2, CXCL3, CXCL5) which are associated to cancer 
growth and progression and with the promotion of tumor angiogenesis and metastasis 
(Keeley et al., 2010; Lazennec and Richmond, 2010; Mantovani et al., 2011). For instance, 
murine models suggest a central role for CXCR2 in promoting lung and pancreatic cancers 
(Ijichi et al., 2011; Keane et al., 2004). More recently, in elegant murine models of 
inflammation-associated skin cancer, colitis-associated or spontaneous intestinal cancer, 
Jamieson and colleagues demonstrated that both inflammation-induced and spontaneous 
carcinogenesis were significantly suppressed following CXCR2 abrogation or neutrophil 
depletion (Jamieson et al., 2012). Moreover, the last identified CXC chemokine, CXCL17 
promoted cancer growth together with the increased infiltration of a myeloid subset of 
CD11b
+
Gr1
+
F4/80
-
 in a murine model of graft tumor (Matsui et al., 2012). 
In a conditional genetic murine model of lung cancer driven by K-ras activation and p53 
inactivation, the spleen was found as a reservoir for TAM and TAN precursors. Indeed 
these cells were relocated from the spleen to the tumor and splenectomy significantly 
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reduced myeloid infiltration in tumors (Cortez-Retamozo et al., 2012). In the same model, 
the authors identified Angiotensin II as a factor playing a central role in amplifying 
hematopoietic self-renewal and myeloid cells progenitors (Cortez-Retamozo et al., 2013). 
In humans, Head and Neck Squamous Cell Carcinoma (HNSCC) cell lines recruited 
neutrophils trough the release of CXCL8 and Macrophage Inhibiting Factor (MIF), both 
identified as mediators of CXCR2-dependent neutrophil chemotaxis (Dumitru et al., 2011; 
Trellakis et al., 2011b). Hepatocellular carcinoma (HCC) cells were also able to recruit 
neutrophils through the production of CXCL8 (Kuang et al., 2011). Moreover, an extensive 
immunohistochemical study of 919 HCC patient biopsies showed association between 
increased CXCL5 expression, neutrophil infiltration and poor patients’ survival (Zhou et 
al., 2012). 
Epidemiological studies indicated an association between TAN and poor clinical 
outcome in metastatic and localized renal cell carcinoma, bronchioloalveolar carcinoma, 
hepatocellular carcinoma, colorectal cancer and head and neck cancer (Donskov, 2013; 
Jensen et al., 2009; Kuang et al., 2011; Rao et al., 2012; Trellakis et al., 2011a; Wislez et 
al., 2003). Moreover, neutrophil infiltration has been associated with higher glioma grade 
(Fossati et al., 1999) and higher aggressive behavior of pancreatic cancer (Reid et al., 
2011). However, in some tumor types, such as gastric and colorectal cancer, the association 
between neutrophil infiltration and patient clinical outcome is not so clear and remains 
controversial (Caruso et al., 2002; Hirt et al., 2013) (Table 3). It is important to take in 
mind that variability in techniques (e.g. immunohistochemistry versus hematoxylin-eosin 
staining), patient datasets, definition, outcomes may account for the variability in the results 
and may explain these controversies (Donskov, 2013). 
V. 3. 2. Neutrophils in tumor initiation and progression 
Genetic instability is a hallmark of cancer (Hanahan and Weinberg, 2011) and 
neutrophil-derived reactive oxygen species (ROS) and nitroxic derivatives have been linked 
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to carcinogenesis already 30 years ago (Weitzman et al., 1985). Indeed, neutrophil-derived 
ROS and derivatives, such as MPO-mediated HOCl have been described to be associated 
with DNA point mutations (Gungor et al., 2010). Moreover, HOCl activates a number of 
neutrophil proteolytic enzymes such as MMP-2, MMP-7, MMP-8 and MMP-9 and 
inactivates the tissue inhibitor of proteases (TIMP-1), thus favoring matrix remodeling, 
invasiveness and metastatic behavior of cancer cells (De Larco et al., 2004).  
Granule proteins were involved in tumor progression. For instance, Neutrophil Elastase 
(NE) could directly promoted cancer. In fact, NE was taken up by lung cancer cells and was 
responsible for the degradation of Insulin Receptor Substrate-1 (IRS-1), a natural inhibitor 
of the PI3K, which usually modulated Platelet-Derived Growth Factor Receptor (PDGFR) 
intracellular signaling. Reduced levels of IRS-1 promoted increased PI3K activation and 
signaling of PDGFR, thus favoring tumor cell proliferation (Houghton et al., 2010). NE has 
also been shown to play a role in neutrophil-related epithelial-to-mesenchymal transition 
(Grosse-Steffen et al., 2012). On the other hand, NE has also an anti-tumoral role. Indeed, 
breast cancer cells took up NE, which cleaved cyclin E, which was then presented as a 
truncated form in HLA-I context and efficiently activated a Cytotoxic T Lymphocytes 
(CTL)-mediated anti-tumor response (Mittendorf et al., 2012). 
Neutrophils have also emerged as an important source of cytokines, which also play 
important roles in cancer initiation and progression. In an in vitro model of breast cancer, 
tumor cells produced GM-CSF, which induced the production of Oncostatin M by 
neutrophils. This IL-6-like cytokine was able to up-regulate VEGF production in breast 
cancer cells, thus promoting tumor cell detachment and invasiveness (Queen et al., 2005).  
In bronchoalveolar carcinoma (BAC), high levels of Hepatocyte Growth Factor (HGF) in 
broncholavage fluid (BAL) correlated with neutrophil infiltration and poor patients’ 
prognosis and this cytokine was able to promote tumor cell migration and invasiveness 
(Wislez et al., 2003) (Imai et al., 2005). In HNSCC patients, neutrophil infiltration was 
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correlated with the expression of CORTACTIN, a protein involved in cellular migration. In 
addition, neutrophils and CORTACTIN significantly correlated with poor patients’ 
outcome (Dumitru et al., 2013). Neutrophils also release TRAIL, which retains important 
anti-tumoral activities (Cassatella, 2006; Hewish et al., 2010). Mycobacterium bovis 
Bacillus Calmette-Guerin (BCG) induced the release of TRAIL from neutrophils, thus 
potentially mediating the anti-cancer effects of BCG in bladder cancer (Kemp et al., 2005). 
Moreover, upon IFN-α stimulation, neutrophils from Chronic Myeloid Leukemia (CML) 
patients released TRAIL, which in turn promoted apoptosis of leukemic cells (Tanaka et al., 
2007; Tecchio et al., 2004). 
Recently, in surgically resected lung cancer patients, TAN were phenotypically and 
functionally characterized as T-stimulatory cells (Eruslanov et al., 2014). Indeed, compared 
with circulating neutrophils, TAN displayed the activated phenotype 
CD62L
low
CD54
+
CXCR1
low
CXCR2
low
, expressed CCR7, CXCR3, CXCR4 and CCR5 and 
produced significant amount of the proinflammatory molecules CCL2, CCL3, CXCL8 and 
IL-6. From the functional point of view, TAN were able to stimulate T cell proliferation 
and IFN-  release, mainly in a contact-dependent manner (Eruslanov et al., 2014). These 
interactions with T cells up-regulated neutrophil expression of co-stimulatory molecules, 
such as CD86 and OX40L, giving rise to a positive feedback loop and suggesting an anti-
tumoral role for TAN in early stages human lung cancers (Eruslanov et al., 2014).  
V. 3. 3. Neutrophils in angiogenesis and metastatic behavior modulation 
Neutrophils can also play a dual role in modulating metastatic behavior of cancer cells. 
Melanoma cells have been described to produce CXCL8, which up-regulated β2-integrin 
expression on neutrophils and favored the interaction with melanoma cell-expressed 
ICAM-1. In turn, this dangerous alliance allowed melanoma cells to transit across the 
endothelium, giving rise to distant metastasis (Huh et al., 2010). Neutrophil-derived NETs 
during sepsis were able to capture circulating tumor cells and favor their engraftment to 
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distant organ sites (Cools-Lartigue et al., 2013). In contrast, in a murine model of 
transplanted breast cancer, neutrophils were accumulated in the pre-metastatic lung and 
inhibited metastasis in a H2O2-dependent manner and upon stimulation with G-CSF and 
tumor-derived CCL2. Accordingly, in this model, neutrophil depletion significantly 
increased the metastatic load (Granot et al., 2011). 
Neutrophils express several angiogenic factors. Firstly, neutrophils are a major source of 
VEGF-A, which is also responsible for the angiogenic activity exerted by CXCL1 in vivo 
(Scapini et al., 2004). In an in vivo model of subcutaneous melanoma and fibrosarcoma and 
in the absence of IFN-β, TAN displayed pro-angiogenic features such as increased 
expression of CXCR4, VEGF-A and MMP-9, associated with a better developed tumor 
vascular architecture (Jablonska et al., 2010). MMP-9 has been described as a potent 
modulator of angiogenesis, able to release the active form of VEGF-A from the 
extracellular matrix (ECM) (Nozawa et al., 2006). In parallel, neutrophils have been 
identified as the major MMP-9 producers in HNSCC and HCC patients (Dumitru et al., 
2012; Kuang et al., 2011; Nozawa et al., 2006) and, unlike other cell types, they deliver 
MMP-9 in a peculiar TIMP-free manner, which enhanced the pro-angiogenic activity of 
MMP-9 (Ardi et al., 2007). On the other hand, intratumoral injection of adenovirus carrying 
MMP-9 gene decreased tumor growth and angiogenesis, suggesting that MMP-9 also 
retains anti-angiogenic functions (Leifler et al., 2013). 
Bv8 (also known as prokineticin-2) is a well-known molecule that promotes neutrophil 
mobilization and angiogenesis. In a tumor xenograft murine model, expression of Bv8 by 
neutrophils was increased by G-CSF (Shojaei et al., 2007) and Bv8 neutralization 
significantly impaired angiogenesis, neutrophil recruitment and tumor development 
(Shojaei et al., 2007). Interestingly, tumors displaying resistance to anti-VEGF therapy 
showed high infiltration of neutrophils and drug resistance was likely related to G-CSF-
induced Bv8 expression. Indeed, anti-G-CSF or anti-Bv8 therapy reduced tumor growth 
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and angiogenesis (Shojaei et al., 2008; Shojaei et al., 2009). In contrast, neutrophils also 
express a number of anti-angiogenic molecules. NE itself can exert anti-angiogenic activity, 
through the cleavage of VEGF and FGF-2 and the generation of angiostatin-like fragments 
from plasminogen, which suppress VEGF and FGF-2 induced angiogenesis (Ai et al., 
2007) (Scapini et al., 2004).  
V. 3. 4. Neutrophil plasticity and heterogeneity in cancer 
Challenging the classical point of view, neutrophils have emerged as cells with 
unsuspected plasticity. In murine models of mesothelioma and lung tumor, it has been 
elegantly demonstrated that neutrophils can be driven by TGF-β to acquire a pro-tumoral 
phenotype (Fridlender et al., 2009). TGF-β block gave rise to a massive neutrophil 
infiltration displaying increased cytotoxicity against tumor cells and characterized by high 
expression of TNF-α, CCL3 and ICAM-1 and low level of the T-cell detrimental molecule 
arginase-1. TGF-β block also lead to a T-cell mediated anti-tumor response, in which 
neutrophils played a pivotal role as effector cells (Fridlender et al., 2009). The potential 
dual role played by neutrophils in tumor microenvironment has been resumed in a new 
proposed paradigm, in which neutrophils can be polarized towards an anti-tumor N1 or 
towards a pro-tumor N2 phenotype in response to signals derived from the 
microenvironment (Figure 7).  
Cancer context is not the only one in which neutrophil plasticity has been proposed. 
Indeed, 15 years ago human neutrophils were shown to acquire a dendritic cell (DC)–like 
phenotype, under the influence of TNF-α and IL-4 in vitro (Oehler et al., 1998) and more 
recently to be reprogrammed into macrophages (Araki et al., 2004). These data have been 
revised by Matsushima and colleagues, who demonstrated that, following in vitro 
stimulation with GM-CSF, both immature and mature murine neutrophils differentiated 
into hybrid populations, with functional properties of both neutrophils and DC (Matsushima 
et al., 2013). The authors also obtained human data, showing neutrophil differentiation into 
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a hybrid population expressing both neutrophil and DC markers upon in vitro treatment 
with GM-CSF, TNF-α and IL-4 for 7 days (Matsushima et al., 2013). Following 
methicillin-resistant Staphylococcus aureus (MRSA) infection, in addition to normal 
neutrophils, two distinct neutrophil subsets were identified, distinguished on the basis of 
cytokine and chemokine production and TLR expression, and displayed different 
susceptibilities to MRSA infection (Tsuda et al., 2004). In addition, a subset of neutrophils 
was identified capable of survive in vitro after 7 days of culture on absence of growth 
factors and presenting phenotypic and functional aspects of giant phagocytic cells 
(Dyugovskaya et al., 2014). 
Taken together, this increasing body of evidence emphasizes the high versatility of 
neutrophils dependent on different settings and could offer new therapeutic approaches 
based on the biology of neutrophils.  
V. 3. 5. Neutrophils, TAN and MDSC 
Cancer development is accompanied by the appearance of a heterogeneous population of 
myeloid cells, namely Myeloid Derived Suppressor Cells (MDSC), which possess 
immunosuppressive and cancer-promoting properties. MDSC are classically distinguished 
between Monocytic (Mo-MDSC) and Granulocytic (G-MDSC) subsets based on 
morphological and phenotypical aspects (Youn and Gabrilovich, 2010). However, this 
distinction is not so defined. Indeed, in tumor-bearing mice, M-MDSC were found to 
acquire phenotypic, morphological and functional features of G-MDSC, due to epigenetic 
silencing of the retinoblastoma gene (Youn et al., 2013).  
In addition, in mice, G-MDSC share many phenotypic and functional features with TAN, 
such as the morphology or the capability to promote immunosuppression via arginase-1 
production (Gabrilovich et al., 2012). Moreover, neutrophils and G-MDSC are usually 
identified by the same membrane markers (CD11b, Gr1 and Ly6G), thus providing an 
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additional confounding element. Therefore, the distinction between neutrophils, TAN and 
MDSC is still debated. 
Some reports describe that renal cell cancer patients display a subset of circulating 
activated neutrophils responsible for immunosuppression of T cell-mediated immune 
response via arginase-1 production, thus accounting for a pro-tumor activity (Rodriguez et 
al., 2009; Schmielau and Finn, 2001). Therefore, in this view, activated neutrophils 
acquired immunosuppressive properties and are considered as G-MDSC. In a genetic 
conditional lung adenocarcinoma model, TAN precursors physically relocated from spleen 
to tumors (Cortez-Retamozo et al., 2012) and, since MDSC accumulated in the spleen of 
tumor-bearing animals, MDSC activities have been at least partially attributed to immature 
neutrophils (Solito et al., 2011; Trellakis et al., 2011b). Accordingly, following GM-CSF 
stimulation, G-MDSC displayed phenotypical and functional characteristics proper of 
neutrophils, suggesting that G-MDSC are immature neutrophils (Youn et al., 2012). These 
immature neutrophilic MDSC have also been reported in cancer patient peripheral blood, 
and their levels correlated with poor patients’ prognosis (Trellakis et al., 2011b). Recently, 
in a multistage mouse model of breast cancer, atypical CD11b
+
Ly6G
+
Rb
low 
neutrophils 
accumulated during tumor progression, in peripheral tissues but not in the primary tumor of 
animals. This neutrophil subset showed T cell-suppressive properties via ROS production. 
Tumor-derived G-CSF was identified as the main mediator for the expansion and 
differentiation of hematopoietic stem cells toward the myeloid lineage and the activation of 
a peculiar myeloid differentiation program in bone marrow (Casbon et al., 2015). These 
evidences further highlight the poorly defined distinction between immunosuppressive 
TAN and G-MDSC. In contrast with these evidences, Fridlender and colleagues performed 
a trascriptomic analysis on peripheral neutrophils, TAN and G-MDSC in tumor-bearing 
mice, and found that TAN and G-MDSC are distinct populations of cells and that naïve 
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neutrophils and G-MDSC are more closely related to each other than to TAN (Fridlender et 
al., 2012).  
VI. COLORECTAL CANCER   
Colorectal cancer (CRC) is the third most frequent tumor in men and the second in 
women worldwide (Ferlay et al., 2010). More than half of the cases occurs in developed 
countries. There is a wide geographical heterogeneity in incidence with the highest 
estimated rates in Oceania, together with part of Europe and North America, and the lowest 
in Western Africa (http://globocan.iarc.fr). Nevertheless, increase in previously low-risk 
populations have been recently described, attributed to changes in dietary habits and 
behaviors associated with Western lifestyle (Center et al., 2009). However, in USA and 
several other countries death rates display a slightly decline, likely to be the result of 
improvements in early detection and treatment (http://globocan.iarc.fr).  
VI. 1. Risk factors and histopathological classification  
A number of risk factors have actually been identified, such as age, male sex, smoking, 
excessive alcohol intake, inflammatory bowel disease, family history of CRC, high 
consumption of red meat, diabetes and obesity (Chan et al., 2011; Fedirko et al., 2011; Jess 
et al., 2012; Jiang et al., 2011; Liang et al., 2009; Ma et al., 2013b; Taylor et al., 2010). In 
contrast, physical activity, aspirin intake and endoscopy with removal of precancerous 
lesions have been described as protective factors (Bosetti et al., 2012; Boyle et al., 2012; 
Brenner et al., 2011). Moreover, low levels of circulating 25-Hydroxy-vitamin D have been 
associated with an increased risk to develop CRC, but the relevance of these data needs to 
be confirmed (Ma et al., 2011). Family history is a well-known risk factor for CRC. 
However, beyond the hereditary forms, which account for less than 10% of cases, genetic 
polymorphisms identified by Genome-Wide association studies and involved in CRC 
development are a matter of debate (Hutter et al., 2012). 
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The current histopathological classification is based on local invasion (T stage), lymph 
node involvement (N stage) and distant metastasis occurrence (M stage). The combination 
of these elements gives rise to the Tumor Node Metastasis (TNM) system, which represents 
the starting point for clinicians to make therapeutic decisions (Table 4 and Table 5). 
However, the usefulness of the TNM system for patients’ outcome prediction has been 
questioned (Galon et al., 2006). For instance, a percentage of stage III and high-risk stage II 
patients, who are recommended for chemotherapy, do not respond to the treatment (Brenner 
et al., 2014). Therefore, additional prognostic and predictive factors are needed to optimize 
patient therapeutic approaches and follow-up.   
VI. 2. Diagnosis and staging  
Diagnosis of CRC is based on histological analysis of biopsy samples obtained during 
endoscopy. Synchronous cancers, present in 2-4 % of patients, need to be excluded by 
complete colonoscopy or Computed Tomography (CT) colonography (Arnaud et al., 1989; 
Park et al., 2012). If not possible before surgery, a complete colon analysis should be 
performed within 6 months after curative intervention. For rectal cancers accurate local 
staging at diagnosis is essential for making therapeutic decisions. To precisely define the 
local extent of the tumor and to distinguish between invasive or non-invasive tumors, 
Ultrasound (US)-endoscopy is the method of choice, together with Magnetic Resonance 
Imaging (MRI) (Puli et al., 2010; Puli et al., 2009). If these methods are employed after 
radiotherapy the results may not be accurate because of the local changes due to radiations.  
Following diagnosis, metastatic localizations, present in about 20% of patients at 
diagnosis, need to be investigated. The most frequent localization is liver and detection by 
imaging (e.g. US, CT and MRI) is mandatory. In a recent meta-analysis including 3391 
patients, MRI was shown to be more sensitive than CT, with the highest sensitivity for 
smaller lesions (Niekel et al., 2010). The sensitivity of abdominal US was considered lower 
compared to the other imaging techniques, even though improvable by using contrast 
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(Floriani et al., 2010; Rafaelsen and Jakobsen, 2011; Sietses et al., 2010). The second most 
frequent localization of metastatic lesions is the lung. The rate of lung metastasis is higher 
in rectal cancers compared to colon cancers (9-18% versus 2% respectively). Therefore, in 
colon-derived tumors chest radiograph can be enough, but in rectal cancer chest CT can be 
justified (Brenner et al., 2014). Even though other organs can be target of metastatic foci 
(e.g. brain, bones), no routine investigation is recommended. Finally, no evidences support 
a role for PET-CT in patients without suspected metastatic lesions (Brenner et al., 2014).  
VI. 3. Etiopathogenesis and Molecular classification 
Classically, CRC classification was based on clinic-pathological aspects (e.g. histological 
type, tumor grade and clinical stage). However, new evidences proposed that molecular 
pathways are involved in CRC initiation and can be associated with patients’ outcome. 
Therefore and despite its heterogeneity and complexity, a classification of CRC based on 
molecular pathways has been proposed (Heinimann, 2013). Based on etiopathogenesis, 
CRC can be classified into inherited or sporadic syndromes. 
VI. 3. 1. Inherited syndromes  
Inherited syndromes account for about 3-5% of CRC and, in these cases, a clear genetic 
alteration can be identified (Jasperson et al., 2010). 
Familial Adenomatous Polyposis (FAP) is an hereditary syndrome in which hundreds of 
adenomatous colorectal polyps occur from the second decade of life, with a risk of 
developing CRC by 100% (Schmoll et al., 2012; Vasen et al., 2015). The key target in the 
management of patients with FAP is cancer prevention. Therefore, annual colonoscopy is 
recommended, with the removal of the suspicious adenomas. In some cases, given the wide 
number of adenomas, prophylactic colectomy can be necessary (Schmoll et al., 2012).  
FAP is an autosomal dominant disease, caused by a germline mutation in the 
adenomatous polyposis coli (APC) gene. In 25% of cases, FAP derives from a “de novo” 
mutation in the APC gene (Half et al., 2009). In a subset of patients with clinical FAP, the 
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phenotype is due to a biallelic mutation (and loss of function) in the base excision repair 
(BER) gene MUTY Homolog (MUTYH), which normally codes for a protein that excises 
from the DNA 8-oxoguanine, an abnormal guanine derived from oxidative stress 
(Markowitz and Bertagnolli, 2009). Given the loss of function of this gene, a highly 
significant excess of somatic G:C-T:A mutations in the APC gene accumulates, giving rise 
to the neoplastic transformation (Cheadle and Sampson, 2003).  
APC gene is a tumor suppressor gene playing important roles in the regulation of the 
Wnt/β-catenin pathway. The oncoprotein β-catenin is part of a transcription factor involved 
in the activation of a number of genes regulating epithelial cell proliferation. APC plays a 
major role in the degradation of β-catenin, thus contributing to the homeostasis of the 
epithelium in the intestinal crypt (Goss and Groden, 2000). Therefore APC gene fulfills the 
criteria of a “gatekeeper gene” which are genes responsible for controlling and inhibiting 
cell growth and enhancing cell death. FAP-related mutations give rise to a truncated APC 
protein, with a subsequent loss of its function, leading to an uncontrolled epithelial 
proliferation and early onset of polyps (Goss and Groden, 2000). Given this accelerated 
proliferation rate, the risk of further genetic mutations involved in cancer development is 
significantly increased. 
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome is the most 
common inherited colon cancer syndrome (Lynch et al., 2015). HNPCC accounts for 2-5% 
of all CRC and is caused by a germline mutation in one of the mismatch repair (MMR) 
genes, which include mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 
6 (MSH6) and postmeiotic segregation increased 2 (PMS2). MMR genes maintain genomic 
stability by repairing replication errors in DNA. Therefore, impaired MMR can lead to the 
accumulation of mutations in others genes (oncogenes or tumor suppressor genes), involved 
in neoplastic transformation. Given the “ubiquitous” functions of MMR genes, HNPCC can 
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also be characterized by the occurrence of extra-intestinal tumors, such as endometrial 
cancer (Lynch et al., 2015).  
MMR genes represent an example of “caretaker genes”, which are responsible for the 
maintenance of the genome integrity and, unlike gatekeepers, are not directly linked to 
tumor promotion. However, mutation in a caretaker gene and loss of protein expression or 
function increased genetic instability and mutation in gatekeeper genes. If a patient inherits 
a mutated caretaker gene copy, he needs three additional mutations to develop a neoplasia: 
a second one in the second allele of the caretaker gene and two additional mutations in both 
copies of a gatekeeper gene. In contrast, if a patient inherits a mutated copy of a gatekeeper 
gene, he only needs an additional mutation, in the second allelic copy, to develop a 
neoplasia. Consequently, mutations in caretaker genes are not expected to cause sporadic 
cancers, since four mutations are needed to give rise to neoplastic transformation (Kinzler 
and Vogelstein, 1997).   
The loss of MMR function is associated with the epiphenomenon of microsatellite 
instability (MSI). Microsatellites consist in short DNA repeats (1-6 base pairs), normally 
scattered in the genome (Hewish et al., 2010). Due to the repetitive nature of these short 
sequences, the susceptibility to replication errors is increased, caused by the slippage of 
DNA polymerases over tandem repeats (Hewish et al., 2010). In normal conditions, these 
mutations are readily recognized and removed by the MMR system. When this machinery 
is not functional, insertions and/or deletions in microsatellites become fixed and the length 
of microsatellites is altered, defining the so-called “Microsatellite Instability”. MSI tumors 
display a peculiar phenotype: poor or mixed differentiation (often mucinous tumors), large 
size, proximal colon location, high level of tumor-infiltrating lymphocytes, rarely 
associated to metastasis (Brenner et al., 2014).  
VI. 3. 2. Sporadic CRC 
57 
 
Sporadic cancers account for about 90% of CRC cases and the molecular pathogenesis 
can be schematically represented in three groups. 
In a first group, the chromosomal instability (CIN) molecular pathway represents the 
most common (70%) molecular pathway responsible for genetic instability and is 
characterized by the accumulation of chromosomal abnormalities (numerical or structural), 
which result in karyotypic variability among cells. These chromosomal rearrangements are 
responsible for the accumulation of mutations in tumor suppressor genes (such as APC, P53 
and SMAD4) causing loss of expression or function, and possible initiation of pathways 
involved in CRC tumorigenesis (Markowitz and Bertagnolli, 2009).  
In a second group of cancers, genomic instability can derive from the inactivation of 
MMR genes. Indeed, MMR mutations can be inherited, such as in HNPCC, or acquired. In 
HNPCC patients, the germline inactivation of one of MMR genes (usually MLH1 or 
MSH2) increases the risk of cancer of 80%. In 15% of CRC, MMR defects are not inherited 
but acquired by biallelic silencing of the promoter region of MLH1 by methylation 
(Markowitz and Bertagnolli, 2009).  
The last group is named CpG Island Methylation Phenotype (CIMP) and is found in 
cancers that present aberrant methylation in selected promoter-associated CpG islands. 
These epigenetic events can lead to loss of expression of the gene or loss of function of the 
protein (Grady and Pritchard, 2014).  
The classification of these three pathways is not strictly defined. Indeed, tumors can 
exhibit aspects of more than one pathway. For instance, CIMP pathway can be responsible 
for sporadic MSI tumors, due to somatic epigenetic silencing of MLH1. In addition, 
activating mutations of the oncogene BRAF take place almost completely in MSI tumors 
when CIMP features are also present. Indeed, BRAF mutations are often associated with 
MLH1 hypermethylation. Therefore, the presence of BRAF mutations can be useful to 
distinguish MSI tumors due to MLH1 methylation from MSI tumors due to germline MMR 
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mutations (Parsons et al., 2012) (Grady and Pritchard, 2014). Moreover, CIMP positive 
tumors can be distinguished in two types: CIMP high, associated with MLH1 methylation 
and BRAF mutations and CIMP low, associated with KRAS mutations (Thiel and 
Ristimaki, 2013).   
Genes and molecular pathways involved in CRC pathogenesis are schematically 
represented in Figure 8.  
VI. 4. Chronic inflammation and CRC  
Patients with Inflammatory Bowel Disease (IBD) display higher risk to develop CRC, 
that increases with duration of colitis, with a risk of 2% at 10 years, 8% at 20 years and 
18% after 30 years of disease (Eaden et al., 2000). Another important risk factor is 
represented by the extent of inflammation, with a risk increasing proportionally to the 
colonic surface involved in colitis. Clinically evaluated disease activity is not associated 
with incidence of CRC (Eaden et al., 2000). Indeed, the degree of active inflammation 
should not be evaluated on the basis of patient symptoms, but it should be estimated on the 
basis of endoscopic and/or histologic criteria. This aspect is supported by the fact that CRC 
can arise in areas of microscopic colitis regardless of clinical activity, supporting a major 
role of the histologically and endoscopically defined inflammation in determining the risk 
of cancer (Mathy et al., 2003). Moreover, patients with severe inflammation non responsive 
to medical therapy (e.g. aminosalicylates, corticosteroids and immunomodulators) often 
undergo colectomy at early stages of disease. Because these patients are no longer at risk 
for colon cancer, this may lead to the false conclusion that severe colitis is not related to 
CRC risk. Patients with a stable active inflammation do not need early-stage colectomy and 
remain at risk for developing CRC. Thus, most patients with IBD who develop CRC have 
quiescent chronic inflammation (Ullman and Itzkowitz, 2011). 
Sporadic and colitis-associated colon cancers (CAC) share genetic and signaling 
pathways alterations, such as Wnt, β-catenin, KRAS, P53, TGF-β and MMR proteins 
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(Ullman and Itzkowitz, 2011). Accordingly, similar frequencies of chromosome instability, 
microsatellite instability and DNA methylation were found between CAC and sporadic 
cancers (Willenbucher et al., 1999) (Ullman and Itzkowitz, 2011). However, CAC presents 
distinct pathogenic sequences compared to sporadic cancer. In particular, sporadic cancer 
arises from a dysplastic lesion, usually the adenomatous polyp, whereas CAC evolves from 
chronic inflammation to dysplasia and carcinoma, without the formation of a well-defined 
adenoma (Ullman and Itzkowitz, 2011). Thus, the classical adenoma-carcinoma sequence 
occurring during sporadic colorectal tumor development is an inflammation-dysplasia-
carcinoma sequence in CAC (Ullman and Itzkowitz, 2011) (Figure 9). Genetic and 
signaling pathways also are altered with a different timing. For instance, the loss of APC 
function occurs early in sporadic CRC but lately and less frequently in CAC development 
(Aust et al., 2002; Lakatos and Lakatos, 2008).  
Inflammation takes part into CRC carcinogenesis through the promotion of chromosomal 
and microsatellite instability, CpG island methylation, by inducing oxidative stress. Indeed, 
in chronically inflamed tissue, tumor initiation can be due to radical oxygen and nitrogen 
species (RONS), released by cells of the innate immune system (Terzic et al., 2010). 
VI. 4. 1. Immune cell infiltration in CRC 
Similarly to other solid malignancies, various types of immune cells infiltrate CRC. 
Innate immune cells, such as neutrophils, mast cells, NK cells, DC and TAM can be 
distinguished in CRC (Atreya and Neurath, 2008). Adaptive immune cells are also recruited 
into colitis-associated and sporadic CRC. The presence of immune cells within the tumors 
can be functionally interpreted as part of immunosurveillance or as tumor promoting 
inflammation. Since sporadic CRC do not occur in the context of pre-existing 
inflammation, it is improbable that inflammation plays a key role for sporadic CRC 
initiation. In contrast, in CAC, IBD always precedes tumor initiation and the risk to develop 
CAC is directly correlated with the severity and duration of active disease. Thus, in CAC, 
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the inflammatory response appears to essentially exert a pro-tumorigenic role. For instance, 
in a CAC mouse model chemically induced by azoxymethane/dextran sodium sulfate 
(AOM/DSS), M2 macrophages were described to exert a critical role in CRC initiation, 
promotion, and metastasis (Wang et al., 2015). In contrast, in sporadic CRC, a well-defined 
balance between immunosurveillance and tumor-promoting inflammation has been 
described. In both CRC and CAC, immunosurveillance can early identify and eliminate 
transformed cells and aberrant crypt foci, keep small tumors at quiescent state (equilibrium) 
and control metastatic foci (Terzic et al., 2010). However, in later stages of carcinogenesis, 
inflammation is involved in tumor-cell survival, proliferation, angiogenesis, and other 
hallmarks of cancer, including immunosuppressive effects (Terzic et al., 2010). Indeed, 
after cancer initiation, the local inflammatory microenvironment favors accumulation of 
further mutations and epigenetic changes. For instance, activated inflammatory cells 
produce reactive oxygen and nitrogen intermediates that can promote DNA damage and 
mutations (Westbrook et al., 2009). 
VI. 4. 2. Role of cytokines in CRC 
A number of tumor-promoting cytokines exert their effect on intestinal epithelial cells 
and trigger activation of oncogenic transcription factors and signaling pathways, such as 
Akt/mammalian target of rapamycin (mTOR), NF- B and STAT3, which play many roles 
in the development of CAC and CRC (Bollrath and Greten, 2009; Bromberg and Wang, 
2009). The role of cytokines in regulation of CAC has been clarified in mouse models of 
CAC and similar mechanisms can be applied to sporadic CRC. For instance, wild type mice 
exposed to AOM/DSS displayed high circulating levels of TNF-  and developed multiple 
colon tumors compared to the controls. In contrast, mice deficient in the receptor TNFR1 
exposed to AOM/DSS displayed reduced inflammation and cancer development. 
Accordingly, the phenotype of wild type mice was reverted following anti-TNF-  treatment 
(Popivanova et al., 2008). A number of pathways are activated downstream TNFR1, but the 
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final activation of NF- B plays a major role in CAC development. Indeed, mice lacking 
NF- B in colon epithelium developed fewer tumors following AOM/DSS treatment; mice 
lacking NF- B in the myeloid compartment developed few and smaller tumors and 
displayed reduced expression of pro-inflammatory mediators such as IL-1 , IL-6 and TNF-
 (Greten et al., 2004). In addition, in an in vivo model of intestinal spontaneous 
carcinogenesis, Karin and colleagues demonstrated that adenoma formation altered the 
epithelial barrier, favoring the invasion of microbial products. These molecules induced 
myeloid cells to produce IL-23, which in turn activated an IL-17-mediated pro-tumoral 
response (Grivennikov et al., 2012). Cytokines such as TNF-α, IL-17, IL-6, IL-1 play a 
major role in promoting colitis-associated tumor development, even though many others 
were found up-regulated in these tumor settings. By contrast, cytokines such as IL-10 and 
TGF-β have been shown to inhibit CRC tumorigenesis (Becker et al., 2004; Popivanova et 
al., 2008; Tang et al., 2005; Terzic et al., 2010). 
VI. 5. Management and therapeutic approaches  
Similarly to other cancer types, CRC should be managed by a multidisciplinary team, 
composed by a gastroenterologist, a medical oncologist, a colorectal surgeon, a pathologist, 
a radiologist and a radiotherapist. All patients should be screened for metastatic 
localizations before starting the treatment. Similarly, patients with rectal cancers should 
undergo further investigations to define the local extent of the disease to assess the need for 
neo-adjuvant therapy. 
Surgery is the first therapeutic approach. For colon cancers, tumor and related lymph 
nodes need to be removed, with the extent of the removal previously determined by staging 
procedures (Stintzing, 2014). For rectal cancers the reference surgical intervention consists 
in the mesorectal excision, i.e. the removal of rectum together with mesorectum and 
mesorectal fascia. The removal of mesorectum is essential, since it contains lymph nodes 
and tumor foci. Moreover, for both colon and rectal tumors, several evidences suggest the 
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importance of clear circumferential margins, i.e. a distance of at least 1 mm between the 
tumor and the resection margin. Indeed, patients with involved resection margins display a 
higher risk of local recurrence and distant metastases (Caricato et al., 2006; Nagtegaal and 
Quirke, 2008). Following the introduction of mesorectal excision in surgical practice, the 
rate of rectal cancer local recurrence has significantly been reduced. Moreover, an 
important trial has shown a further increase in recurrence free survival following neo-
adjuvant therapy (van Gijn et al., 2011). However, which patients need to undergo adjuvant 
chemotherapy and which regimen is the optimal one need to be clearly established. Given 
the optimal prognosis, stage I colon and rectal cancer patients should not undergo any 
adjuvant treatment following surgery. Stage III patients will benefit of the adjuvant 
treatment, whereas for stage II patient the adjuvant treatment-derived benefit is not so clear. 
Actually, for stage II rectal cancer patients benefit is generally accepted for locally invasive 
T4 or T3 tumors infiltrating the mesorectal fascia. In Stage II colon cancer patients, 
adjuvant chemotherapy is actually recommended only in selected “high-risk” conditions, 
such as T4 tumors, perforation or bowel obstruction and < 12 lymph nodes removed 
(Brenner et al., 2014).  
Stage III colon cancer patients are recommended to undergo adjuvant chemotherapy, 
given the risk of local recurrence (about 20%). Standard regimens include 5-FluoroUracyle 
(5-FU) or platin compounds and significantly reduce the risk of recurrence (Gill et al., 
2004). 5-FU is a pyrimidine analogue, which inhibits the enzyme thymidylate synthase, 
thus decreasing the production of deossiTymidineMonoPhosphate (dTMP). It can also 
mimic pyrimidine function, since 5-FU is incorporated into DNA (via dUMP or dTMP) or 
RNA (via UTP), leading to cytotoxic actions (e.g. DNA strand breakage and decreased 
protein synthesis). As an alternative, capecitabine, which is a pro-drug of 5-FU, has been 
also shown to be efficient (Twelves et al., 2012). To further improve disease free survival, 
oxaliplatin has been added to 5-FU (FOLFOX) or capecitabine (XELOX), showing a 
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significant increase in 5-years DFS (Andre et al., 2009; Haller et al., 2011). However, one 
study showed that therapeutic advantage of oxaliplatin was observed only in younger 
patients (Yothers et al., 2011) suggesting that further investigations are needed. Other 
approaches have been tested such as anti-VEGF or anti-Epidermal Growth Factor Receptor 
(EGFR) drugs. However and surprisingly, in stage III patients, addition of these drugs to 
oxaliplatin-based regimens as well as addition of the topoisomerase I inhibitor irinotecan to 
5-FU did not show any significant effect on patient DFS (Alberts et al., 2012; de Gramont 
et al., 2012; Van Cutsem et al., 2009). 
With the regard of stage IV patients, resectable metastases should be surgically removed; 
if unresectable, patients should undergo palliative chemotherapy. With the advent of new 
biological drugs such as anti-VEGF (bevacizumab, aflibercept) and anti-EGFR (cetuximab 
or panitumumab) given alone or in combination to standard chemotherapy regimens, the 
survival of stage IV patients is improved, up to 20 months in some cases (Arnold and 
Seufferlein, 2010; Heinemann et al., 2014; Schwartzberg et al., 2014; Stintzing, 2014). In 
some cases, metastasis unresectable at time of diagnosis become resectable following 
chemotherapy, thus conferring a significant advantage in DFS (Brenner et al., 2014). 
Expectedly, the characteristics of the chemotherapeutic programs need to be carefully 
defined depending on patient clinical conditions and features, such as age and 
comorbidities.   
VI. 6. Molecular markers of prognosis and prediction of therapeutic response  
The milestone of the current guidelines for CRC treatment is the TNM system described 
by the American Joint Committee on Cancer (AJCC) in collaboration with International 
Union for Cancer Control (UICC) (Tables 4 and 5). As already mentioned, this well-
known standard classification scheme is based on the anatomical extent of the tumor at 
diagnosis and is widely established. However, the clinical reliability and usefulness of this 
system have been recently questioned (Galon et al., 2006). Indeed, clinical practice showed 
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that patients at the same TNM stage could differently respond to a similar treatment and 
have different disease progression. For stage I or low-risk stage II patients, guidelines do 
not recommend adjuvant therapy after radical surgery because these patients are considered 
completely cured and display long term survival. However, about 10% of stage I and 20% 
of stage II patients undergo recurrence or metastasis (Mei et al., 2014). To move to a 
“patient-tailored” medicine, in the last decade a huge amount of work has been made in 
order to find new prognostic and predictive markers useful to predict progression rates and 
response to chemotherapy (Di Caro et al., 2013). 
V. 6. 1. Microsatellite instability  
Besides the identification of hereditary cases of CRC, microsatellite instability 
investigation provides additional information to orientate prognosis and predict therapy 
response. Stage II and stage III patients with MSI cancers display better prognosis than 
patients with microsatellite stable (MSS) tumors (Barrasa Shaw et al., 2009; Benatti et al., 
2005; Chang et al., 2006; Malesci et al., 2007). Indeed, a metanalysis including 7642 CRC 
patients distributed in 32 studies showed a survival advantage for patients with MSI 
compared to patients with MSS (hazard ratio (HR) of 0.65 (95% CI 0.59-0.7) (Popat et al., 
2005). In contrast, MSI CRC patients do not respond to 5-FU-based adjuvant therapy but 
show a better response to irinotecan (Bertagnolli et al., 2009; Fallik et al., 2003; Sargent et 
al., 2010). These results support the need of molecular tumor analysis in all CRC patients 
that are candidate to undergo adjuvant chemotherapy. 
V. 6. 2. KRAS and BRAF  
The proto-oncogene KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) 
encodes for a hydrolase enzyme that can bind and hydrolyze guanosine triphosphate (GTP) 
(Schubbert et al., 2007). K-RAS is involved in the RAS-RAF-MAPK pathway, which is 
activated during carcinogenesis (Williams et al., 2006). Accordingly, KRAS mutations are 
found in about 40% of CRC and have been proposed to be an early event in CRC 
65 
 
carcinogenesis (Grady and Pritchard, 2014). Prognostic role for KRAS mutations in CRC 
remains controversial, likely due to the need of considering KRAS mutations together with 
the specific mutations on specific codons (Cerottini et al., 1998; Moerkerk et al., 1994). In 
addition, contrasting results found in different studies can be due to variability in sample 
sizes and patient datasets. 
The BRAF (v-raf murine sarcoma viral oncogene homolog B) gene encodes for a 
serine/threonine kinase, activated by KRAS-GTP. More in details, BRAF protein is 
recruited to the membrane and activated by KRAS. In turn, active BRAF induces the 
activation of MAPK (Mitogen-activated protein kinases) leading to activation of many 
transcription factors, which regulate cell proliferation and survival. KRAS and BRAF 
mutations are actually considered mutually exclusive in CRC (Rajagopalan et al., 2002). 
BRAF mutations were associated with poor patient survival especially in MSS CRC. The 
prognostic role of BRAF mutations in MSI tumors is not clearly defined (Ogino et al., 
2009; Thiel and Ristimaki, 2013). Even though the effects of KRAS and BRAF mutations 
on patient prognosis remain controversial, their predictive role in response to anti-EGFR 
therapy in metastatic CRC patient is accepted. Indeed, EGFR engagement activates a 
signaling cascade via KRAS/BRAF and in case of mutations in KRAS anti-EGFR therapy 
response rates were reduced from 20% to about 0% (Amado et al., 2008). Similarly, KRAS 
wilde-type BRAF mutated tumors do not respond to anti-EGF-based chemotherapy (Di 
Nicolantonio et al., 2008).  
V. 6. 3. Prognostic and predictive role of immune cell infiltration in CRC 
In the view of an even more personalized medicine, infiltration of leukocytes within the 
tumor may have a prognostic role for patients with CRC (Bindea et al., 2013).  
In 1986 infiltration of immune cells was first described as an independent prognostic 
factor in CRC patients (Jass, 1986). Following this first report, number of studies showed 
that type, density and location of immune cells have a prognostic role for patient outcome 
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(Galon et al., 2006; Mei et al., 2014). However, differences in methodological approaches 
(e.g. tissue microarray, patient datasets) and discrepancies in results suggest that further 
studies are needed to define the prognostic role of leukocyte subsets in CRC. Recently, a 
study reported that the immune infiltrate composition changes according to tumor stage 
(Bindea et al., 2013). 
Among immune cells infiltrating CRC, lymphocytes (CD3
+
 cells, CD8
+
 cells and 
FOXP3
+
cells) were significantly associated with favorable patient prognosis (Laghi et al., 
2009; Mei et al., 2014; Pages et al., 2005; Salama et al., 2009). Microarray analysis 
revealed two clusters of patients with CRC. Cluster 1 was characterized by Th1, Tγδ, 
cytotoxic T cells and macrophage signature and was associated with good prognosis. 
Cluster 2 was characterized by a Th2, Th17, Treg and NK cell signature and was associated 
with poor prognosis (Bindea et al., 2013). Analysis of immune populations in situ revealed 
that most of T cell markers, including CD8
+
 and Th1 were significantly associated with a 
good prognosis, whereas Th17 cells negatively influenced the patients’ outcome (Bindea et 
al., 2013). In addition, B cell infiltration was associated with patient increased survival 
(Bindea et al., 2013). Accordingly, a recent study identified the tertiary lymphoid tissue 
(TLT) as a peculiar histological entity, rich in CD20
+
 B cells and CD3
+
 lymphocytes, which 
dynamically interact. In this study, CD3
+
 tumor-infiltrating lymphocytes efficiently 
correlated with TLT and predicted better patients’ outcome (Di Caro et al., 2014). 
Recently, a study proposed the calculation of an “immunoscore” based on the density of 
total CD3
+
 and cytotoxic CD8
+
 T lymphocytes, both in the core and at the invasive margin. 
This immunoscore could be a useful prognostic marker in patients with rectal cancer treated 
with primary surgery and could be a predictive marker for response to preoperative chemio-
radiotherapy. This new scoring system is named “Immunoscore” and represents a new 
promising instrument for prognostic stratification of colorectal cancer (Galon et al., 2014).  
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In contrast to the adaptive immunity, the prognostic role of innate immune cell 
infiltration has not been analyzed in a such complete extent and controversial data have 
been reported for macrophages (Forssell et al., 2007; Grizzi et al., 2013; Kaler et al., 2010) 
and neutrophils (Hirt et al., 2013; Rao et al., 2012). More in details, the role of 
macrophages in CRC is controversial, with some evidence suggesting that their pro- or anti-
tumor functions may depend on their tumor location (e.g. invasive front versus intratumoral 
compartment) (Erreni et al., 2011). Studies are mostly in favor of an association between 
high macrophage infiltration and better patient outcome (Edin et al., 2013; Forssell et al., 
2007). 
The prognostic role of neutrophil infiltration in tumors has been described above (see pg 
38). In CRC, first studies had indicated an association between neutrophil infiltration and 
good patients’ prognosis (Klintrup et al., 2005; Nagtegaal et al., 2001; Nielsen et al., 1999). 
In contrast, more recent works proposed that tumor-infiltrating neutrophils were associated 
with poor patients’ outcome (Akishima-Fukasawa et al., 2011; Rao et al., 2012). The most 
relevant published data on prognostic role of neutrophil infiltration in tumors are 
summarized in Table 3. 
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AIM 
The aim of this study was to evaluate the role of neutrophils in human CRC, and in 
particular: 
- to find a specific marker to identify neutrophils in CRC tissues by 
Immunohistochemistry, with particular regard to Myeloperoxidase (MPO) and CD66b; 
- to evaluate neutrophil infiltration in Stage I-IV Colorectal Cancer (CRC) tissues from 
patients who underwent surgical resection for CRC at Humanitas Clinical and Research 
Center, Rozzano (MI), by immunohistochemistry; 
- to investigate correlations between clinic-pathological aspects and tumor-infiltrating 
neutrophils in CRC and evaluate their prognostic value on patient survival;  
- to evaluate the role of tumor-infiltrating neutrophils in predicting chemotherapy 
response in Stage III CRC patients; 
- to define the phenotypical and functional aspects of tumor-infiltrating neutrophils in 
CRC, in particular whether a cross-talk exists between tumor cells and infiltrating 
neutrophils;  
- to investigate whether tumor cells could modify neutrophil biology and whether 
tumor-infiltrating neutrophils could modulate tumor cell behavior. 
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RESULTS 
The temporal dynamics of CD66b
+
 neutrophil infiltration during CRC  
Today, there is no consensus on the method for the staining of neutrophils in cancer 
tissues. Therefore, we conducted a first set of experiments to characterize a specific 
neutrophil marker in CRC tissues, focusing our attention on myeloperoxidase (MPO) and 
CD66b, two molecules used as neutrophil markers in CRC tissues (Rao et al., 2012; 
Roncucci et al., 2008). Double staining in immunohistochemistry for CD66b plus MPO and 
CD68 plus MPO revealed that all CD66b
+ 
cells were
 
MPO
+
, corresponding to neutrophils. 
However, a population of CD66b
-
 MPO
+ 
cells and CD68
+
 MPO
+
, likely to be not fully 
mature macrophages, was also observed (Figure 10a). Therefore, we evaluated the pattern 
and density of neutrophil infiltration in CRC tissues by using CD66b as neutrophil marker 
and a computer-aided imaging analyzing system. To bring a robust and uncontroversial 
conclusion, we analyzed the immunoreactive area (IRA) for CD66b both in the intratumoral 
compartment (IT) and in the invasive margin (IM) of whole tissue section (Figure 10b). 
Three distinct regions both in the IT and IM compartments were blindly analyzed.  
We compared the infiltration of neutrophils found in whole CRC tissue sections at 
different cancer stages. Importantly, the infiltration of neutrophils appeared to evolve with 
tumor progression. Indeed, the density of tumor-infiltrating neutrophils increased from 
stage I to stage III, followed by a dramatic decrease from stage III to stage IV (p=0.005; 
Figure 10c).  
The association between neutrophil infiltration, clinicopathologic features and 
survival of CRC patients 
Patient demographics and clinicopathologic features are detailed in table 6. ROC curve 
analysis was employed to define the cut-off value for high CD66b
+
 IRA. Linear regression 
analysis revealed that no clinicopathological parameter was associated with CD66b
+
 IRA 
both in the IM and in the IT (Table 6). However, we observed a trend towards a positive 
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association between vascular invasion and neutrophil infiltration both in the IM and the IT 
(Table 6).  
As expected, univariate analysis revealed that microsatellite status, TNM staging and 
vascular invasion significantly influenced disease-specific survival (DSS) and disease-free 
survival (DFS) (Table 7). Surprisingly, high CD66b
+
 IRA, both in the IM (i.e. 49.2% of 
tumor samples) and in the IT (i.e. 50.7% of tumor samples), was significantly associated 
with better DSS (p=0.003 and p=0.002, respectively) and better DFS (p= 0.03 for both IM 
and IT) (Table 7). These results were confirmed by Kaplan-Meier curves showing 
significantly better DSS and DFS in patients with tumors highly infiltrated by CD66b
+
 cells 
(Figure 11).  
In order to assess whether the prognostic value of CD66b
+
 IRA can be influenced by 
other variables, we combined clinicopathologic features with CD66b
+
 IRA scores in 
multivariate analysis. We found that higher density of neutrophils found in the IT was an 
independent prognostic marker for better DSS (Hazard ratio (HR)=0.47; p=0.03) and DFS 
(HR=0.58; p=0.05) (Table 7). Regarding the other variables, clinical stage and vascular 
invasion were also independent prognostic predictors but as risk factors for poor DSS and 
DFS (Table 7).  
Predictive significance of neutrophil infiltration for chemotherapy response   
Several lines of evidence have reported that successful chemotherapy depends on both 
innate and adaptive immunity (Anitei et al., 2014b; Ma et al., 2013a; Medina-Echeverz et 
al., 2011). However, the clinical significance and role of neutrophils remain to be 
discovered. Thus, we recruited new DNA mismatch repair-proficient patients with Stage III 
CRC (n=178), for whom 5-fluorouracil (5-FU) chemotherapy was recommended (Schmoll 
et al., 2012). Firstly and to gain deeper insight about the localization of neutrophils in CRC 
tissue, we compared the density of neutrophils found in the IM and in the IT. Interestingly, 
higher neutrophil density was found in the IT compared with the IM (p=0.02, Figure 12a). 
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Since primary tumor is surgically removed before chemotherapy treatment, we evaluated 
whether a correlation existed between the CD66b
+
 IRA found in primary tumor (IT) and in 
metastatic lymph node. Analysis showed that metastatic lymph node CD66b
+
 IRA was 
significantly associated with primary tumor CD66b
+
 IRA (p=0.03, Figure 12b). Therefore, 
our data suggest that the density of neutrophils found in the metastatic lymph nodes mirrors 
their density in the primary tumor. 
Thus, we next assessed whether CD66b
+
 IRA found in the IT had a predictive 
significance for 5-FU-based chemotherapy response. Analysis of the whole cohort showed 
that age, tumor grade, vascular invasion and nodal status were prognostic markers for poor 
survival in stage III CRC patients (Table 8). Importantly, we found that a trend towards 
better DFS was seen in patients treated with 5-FU (HR=0.61; p=0.06) and in patients with 
higher neutrophil infiltration in the IT (HR=0.61; p=0.12). Multivariate regression Cox 
analysis revealed that an interaction exists between 5-FU treatment and CD66b
+
 IRA 
(p=0.009). Accordingly, 5-FU-based chemotherapy and CD66b
+
 IRA were not independent 
predictive markers for DFS in these patients (Table 8).  
The predictive significance of CD66b
+
 IRA could be influenced by the heterogeneity of 
the population, due to the combined presence of treated and untreated patients. Therefore, 
we assessed the predictive significance of CD66b
+
 IRA in treated versus untreated patients. 
As shown in figure 12, higher density of neutrophils in the IT was associated with better 
prognosis in 5-FU treated patients (Figure 12c, HR=0.42; p=0.01) but was irrelevant to 
predict the prognosis of untreated patients (Figure 12d, HR=1.79; p=0.26) or combined 
treated and untreated patients (Figure 12e, HR=0.64; p=0.12).  
All together, these results indicate that density of neutrophils found in the primary tumor 
had predictive significance for chemotherapy response and could reflect a more systemic 
effect of neutrophils, such as an antitumor activity beyond the primary tumor.  
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Regulation of neutrophil chemotaxis and survival by CRC cell lines  
In a next set of in vitro experiments, we assessed whether CRC cell lines (i.e. SW480, 
HT29 and SW620) have the ability to modulate the biology of neutrophils. We found that 
CRC cell lines-derived conditioned media (CM) induced chemotaxis of neutrophils (Figure 
13a). Accordingly, CRC cell lines produced CXCL8, CXCL1 and CXCL2 chemokines 
both at the mRNA and protein levels (Figure 13b-d and data not shown). To verify the 
involvement of these chemokines, neutrophils were cultured with CM in presence or 
absence of a small inhibitor molecule of CXCR1/CXCR2 (i.e. Reparixin), a selective non-
peptide inhibitor of CXCR2 (i.e. SB225002), or the G-coupled receptor inhibitor, pertussis 
toxin (PTX). All these treatments blocked the chemotactic activity of CM towards 
neutrophils, showing that CRC cell lines produced soluble molecules with chemotactic 
activity for neutrophils and acting through CXCR1/2 (Figure 13e).  
We next investigated whether CM modulate neutrophil lifespan. By FACS analysis, we 
observed that survival of neutrophils was dramatically increased in presence of CM 
compared to control medium (Figure 14a). On day 3, almost all neutrophils cultured in the 
control medium were apoptotic (live cells <1%). In contrast, a significant proportion of 
neutrophils cultured in the presence of CM were live cells (43.6± 8%, 41.9± 9% and 24.15± 
4.8%  (mean ± SEM) cultured in CM from SW480, HT29 and SW620, respectively), 
suggesting that CRC cell lines produced soluble mediators that increased neutrophil 
survival (Figure 14a). To dissect the molecular mechanism for this pro-survival effect, we 
evaluated the presence of soluble factors known to increase the neutrophil lifespan in CM. 
We failed to detect G-CSF, IL-1β and TNF-α (data not shown). In contrast, CRC cell lines 
produced GM-CSF (Figure 14b) and blocking antibody against this growth factor totally 
blocked the pro-survival effect of CM (Figure 14c). In addition, morphological changes in 
neutrophils, due to cell attachment and spreading and known to occur upon stimulation by 
inflammatory cytokines and growth factors (Kutsuna et al., 2004), were observed when 
73 
 
cells were cultured in CM and were inhibited in presence of GM-CSF blocking antibody 
(Figure 14d). Therefore, our data suggest that GM-CSF was the main soluble factor 
produced by CRC cell lines with pro-survival and pro-activating effects for neutrophils.  
Neutrophils display a cytostatic activity towards CRC cell lines 
We next evaluated whether neutrophils cultured or not with CM had a cytotoxic or 
cytostatic activity towards CRC cell lines. CM entrained-neutrophils for 30min or naïve 
neutrophils were co-cultured with CFSE-labeled HT29 cells for 24h at a 20:1 neutrophil to 
tumor cell ratio. Taking into account the high number of circulating neutrophils, this co-
culture ratio is probably an underestimation of the actual in vivo ratio, as previously 
suggested (Granot et al., 2011). We observed that the presence of neutrophils significantly 
reduced the number of HT29 (Figure 15a). A similar effect was observed using either 
neutrophils entrained in CM or non-entrained neutrophils, suggesting that neutrophils can 
be stimulated during the co-culture. We next assessed whether HT29 number reduction was 
a consequence of a cytotoxic or cytostatic activity of neutrophils towards CRC cell lines. 
Neutrophils did not modulate the percentage of apoptotic HT29 cells, suggesting that they 
did not display a cytotoxic activity towards HT29 cells (Figure 15b). Therefore, we tested 
the cytostatic activity of neutrophils by measuring HT29 cells proliferation by dilution of 
CFSE staining. We observed that addition neutrophils reduced the proliferation of HT29 
cells (Figure 15c). 5-FU, used as positive control, increased the frequency of apoptotic 
HT29 cells and decreased cell proliferation (Figure 15a-c). Collectively, these data suggest 
that neutrophils display an anti-tumoral activity towards CRC cells due to a direct cytostatic 
effect. 
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MATERIALS AND METHODS 
 
Patients 
Cancer-tissue specimens from 271 patients who consecutively underwent resective 
surgery for colorectal cancer were retrieved from previous series (Laghi et al., 2009). For 
each patient included in this study, demographics and clinical data at diagnosis were 
available through the institutional intranet. A clinical database was prepared by 
investigators who were blinded to the results of molecular and immunological phenotype of 
the cancers. A single pathologist, who was also unaware of the molecular phenotypes, 
reviewed tissue specimens. Patients who underwent neoadjuvant radiotherapy for rectal 
cancer were excluded because of the possibility of interference with the assessment of the 
local immune response. The presence of metastasis at diagnosis was assessed in all patients 
by combining histopathological findings, surgical records (including intra-operative liver 
ultrasonography), and perioperative imaging (abdominal CT and chest radiography in all 
patients). The observation period started immediately after surgery. To monitor postsurgical 
tumor recurrences, thoraco-abdominal CT, abdominal ultrasonography, and chest 
radiography were done according to common protocols for surveillance. Chemotherapy 
treatment was administered and allocated according to adjuvant protocols in use at the time 
of surgery. The study was approved by the ethical committee of the Humanitas Clinical and 
Research Center, and written informed consent was obtained by the referring physician at 
the time of surgery. 
Study design 
Tissue specimens of patients with colorectal cancer who consecutively underwent radical 
surgical resection at the Humanitas Clinical and Research Center (Rozzano, Milan, Italy) 
from January 1997 to November 2006 were retrospectively studied. A clinical retrospective 
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database containing demographics, clinical, and histopathologic data was assembled from 
the institutional intranet by the investigators who were blinded to the results of the 
morphologic analysis assembled. All these variables, together with the values of CD66b
+
 
IRA, were tested as predictors of the patients’ outcome. The outcome of patients who 
undergo radical resection of colorectal cancer can be affected by an event defined as 
cancer-related death of patient (disease specific survival - DSS) or any local tumor 
recurrences/metachronous distant organ metastases (disease-free survival - DFS). In order 
to detect or exclude any postsurgical tumor recurrences, patients underwent abdominal 
ultrasonography, thoraco-abdominal computed tomography and chest radiography, 
according to common protocols for surveillance. The observation period started 
immediately after the surgical procedure. The mean follow-up period of the cohort studied 
was 4.78 years (SD=2.78) for DSS and 4.38 years (SD=2.92) for DFS. The detection of 
tumor recurrence or death was computed from diagnosis until data were censored on May 
30, 2010.  
Immunohistochemistry and microsatellite status 
Formalin-fixed and paraffin-embedded thin sections of tumor (2μm) were deparaffinised 
and exposed to antigen unmasking solution in DIVA buffer 1X (Biocare Medical, CA, 
USA). Endogenous peroxidase was blocked with 3% hydrogen peroxide for 20 min at room 
temperature. Primary mouse monoclonal anti-CD66b antibody (clone G10F5; BD 
Pharmingen, CA, USA) was applied for 1 h at room temperature. Reactive sites were 
identified by exposure to a secondary antibody (HRP rabbit/mouse; MACH 4 Biocare) for 
30 min at room temperature. Immunoperoxidase staining was then obtained by using 
diaminobenzidine (Dako, CA, USA) as chromogen. The slides were finally counterstained 
with haematoxylin. CD66b
+
 IRA was measured in three randomly selected and non-
contiguous microscopic areas encompassing the deep front of tumor invasion and in three 
randomly selected and non-contiguous microscopic areas in the intratumoral compartment. 
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Density of CD66
+
 cells was evaluated by a computer-assisted measurement, as previously 
described (Di Caro et al., 2014; Laghi et al., 2009). With regard of invasive margin, for 
each selected area, the cancer tissue had to represent approximately 50% of the entire 
microscopic field. The pathologist who selected the areas of interest was blinded to tumor 
microsatellite status and to any patients’ clinical data. For each selected region, a digital 
image was captured (Figure 10b). Given that an accurate optical count of CD66b
+
 cells 
was not feasible in the presence of very dense infiltrates or agglomerates, we did not 
attempt to convert area values to number of cells. For each tumor, the mean of values 
obtained in three distinct regions was calculated and used for the subsequent analysis of 
data. In some experiments rabbit polyclonal anti-MPO antibody (Dako) were used with 
mouse monoclonal anti-CD68 (clone PG-M1; Dako) and mouse monoclonal anti-CD66b 
antibody. After washed, slides were incubated with the goat anti-rabbit poly-horseradish 
peroxidase (HRP) and goat anti-mouse poly-alkaline phosphatase (AP). AP reaction was 
obtained using red chromogen (Warp red Chromogen Kit; Biocare Medical) and HRP 
reaction was obtained using a green chromogen (Vina Green Chromogen Kit, Biocare 
Medical). Microsatellite status was determined preliminarily for all cancers included in the 
study by testing instability at mononucleotide repeats, as previously described (Laghi et al., 
2012).  
Statistical analysis 
Associations between the extent of CD66b
+
 IRA and patients characteristics or tumor 
features were tested by linear regression analysis. A Cox proportional hazards model was 
constructed to assess the clinical significance of CD66b
+
 IRA, as well as other clinico-
pathological features, for patients’ outcome.  
The Receiver Operative Characteristic (ROC) curve analysis, which maximizes both 
sensitivity and specificity of a marker (Heagerty et al., 2000), was used to select the 
CD66b
+
 IRA cut-off score. Tumors were distributed into two groups designed as “high 
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CD66b” and “low CD66b” based on the indicated cut-off value of CD66b+ IRA. Kaplan-
Meier curves of disease specific (DSS) and disease-free survival (DFS) were plotted. In the 
ROC curve analysis, patients’ outcomes were dichotomized by survival (death vs alive) for 
DSS and relapse (local failure/distant metastasis vs no local failure/distant metastasis) for 
DFS, respectively. The detection of tumor recurrence or death was computed from 
diagnosis until data were censored on May 30, 2010. The log-rank test was used to compare 
the curves of patient subgroups. A Cox proportional hazard ratio model was used to assess 
whether CD66b
+
 IRA, as well as other clinicopathological features were independent 
prognostic factors for patient survival. Mann-Whitney U test, Student’s t test, Spearman’s 
correlation, Pearson’s correlation, Cusik’s trend test were used as specified. P ≤ 0.05 was 
considered significant. For each test, only two-sided and P ≤ 0.05 was considered 
significant. Analyses were done using Epi Info version 3.4.3, StatsDirect Statistical 
software (version 2.5) and GraphPad Prism software (Version 4.1).  
Cell cultures and tumor-conditioned media preparation 
The human colon tumor cell lines SW480, HT29 and SW620 (ATCC, VA, USA) were 
cultured and maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS, 50 
U/mL penicillin/streptomycin and 2 mM L-glutamine (Lonza). Conditioned media were 
obtained and used as follows. Cells were plated at 10-20% confluence in six well tissue 
cultures. Once cells had reached a confluence of 85-90%, cell culture media were replaced 
by fresh media containing RPMI 1640 supplemented with 0.5% FBS. After 24 h, the 
conditioned medium (CM) was collected and filtered at 0.20 µm. Supernatants were stored 
at -20°C. All cell lines were routinely checked for mycoplasma contamination.  
Neutrophil purification and culture 
Leukocytes from peripheral blood of healthy donors were separated from erythrocytes by 
Dextran sedimentation. Neutrophils were purified by Ficoll-Paque density gradient 
centrifugation followed by Percoll (65%) density gradient centrifugation, as previously 
78 
 
described (Muzio et al., 1994). These cells were >99% neutrophils as evaluated by flow 
cytometry analysis by using the following antibodies, anti-CD3, anti-CD14, anti-CD15, 
anti-CD11b, anti-CD62L, anti-CD66b (all from BD bioscience, CA, USA) and anti-CD11b 
(eBiosciences, CA, USA). Analysis was performed by using FACS Canto II and FACS 
Diva software (BD bioscience). Spontaneous activation of neutrophils was analyzed by 
evaluating CD11b and L-selectin expression by FACS analysis before and after isolation; 
only L-selectin
+
CD11b
low
 (non activated) neutrophils were used in this study (data not 
shown).  
Quantification of soluble factors in culture supernatants 
Production of CXCL8, CXCL1, CXCL2, G-CSF, GM-CSF, TNF-α and IL-1β by CRC 
cell lines was analyzed by ELISA (R&D DuoSet ELISA Development System), according 
to the protocols provided by the manufacturer. A Versamax microplate reader (Molecular 
Devices Corporation –Biospa) was used to determine sample absorbance at 450 nm. 
Cell migration assay 
Migration of neutrophils towards CM and CXCL8 was evaluated by using a Boyden 
chamber (Neuroprobe, CA, USA) assay. Briefly, 30µl of CM or control medium (RPMI 
1640 supplemented with 0.5% FCS) were added to the lower wells of the chamber. A 
polyvinylpyrrolidone-free polycarbonate filter (5 µm pore size; Neuroprobe) was layered 
onto the wells and covered with a silicon gasket and the top plate. Fifty microliters of cell 
suspension (7.5x10
4
 neutrophils) were seeded in the upper chamber. In some experiments, 
anti-CXCR1/2 (Reparixin, 1uM), anti-CXCR2 (SB225002, 20 nM), PTX (100 ng/ml) or 
vehicle (DMSO) were added to the cell suspension. The chamber was incubated at 37°C in 
5% CO2 and 95% air atmosphere for 60 min. At the end of the incubation, filters were 
removed and stained with Diff-Quik (Baxter, Rome, Italy). Twenty high power oil-
immersion fields were counted for each condition in triplicates. 
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Apoptosis assay and morphological analysis of neutrophils 
Purified neutrophils (10
6
 cells/mL) were cultured with SW480, HT29 and SW620 CM 
with or without mouse monoclonal anti-GM-CSF blocking antibody at 10 µg/ml (Clone 
3209, R&D Systems) or the corresponding control isotype (R&D Systems). For each time 
point, neutrophils were stained with FITC-conjugated AnnexinV and propidium iodide (PI) 
according to the manufacturer’s instructions (Invitrogen). Live cells were characterized as 
double negative AnnexinV
- 
PI
- 
cells.
 
Analysis was performed by using FACS Canto II and 
FACS Diva software (BD). After 24 hours of culture, optical images were acquired with 
Olympus IX53 upright light microscope at 20x magnification. 
Cytotoxic and cytostatic assays  
HT29 cells (5x10
4
 cells)
 
were plated on a 24-well plate for 48hours and then stained with 
CFSE (carboxyfluorescein diacetate succinimidyl ester), according to the manufacterer’s 
instruction (Invitrogen). After wash, cells were cultured in RPMI 1640 supplemented with 
10% FBS for 4 hours. Neutrophils isolated from healthy donors peripheral blood, were pre-
incubated with CM or control medium and added to the HT29 culture at a 20:1 neutrophil 
to tumor cell ratio. After 24 hours, cells were stained with APC-conjugated Annexin-V and 
PI according to the manufacturer’s instructions (Invitrogen). Analysis was performed by 
using FACS Canto II and FACS Diva software (BD).  
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DISCUSSION 
Personalized medicine is an important target for clinicians and researchers. In this view, 
the identification of independent prognostic and predictive markers plays an essential role. 
Prognostic markers give information on patients’ outcome and can be useful to orientate 
therapeutic decisions. Predictive markers give information as to the likely response to 
therapeutic regimens. 
Colorectal cancer is a complex and heterogeneous disease. Therefore, universal 
prognostic and predictive markers, to improve patients’ follow-up and choose the most 
adequate treatment protocol for each cancer patient, are still needed. Indeed, the usefulness 
of the international reference TNM system, currently in use for patients’ outcome 
prediction, has been questioned (Galon et al., 2006).  
In clinical research studies on CRC, the power to predict which cancer patient will 
display a survival advantage from 5-FU-based chemotherapy has been even more difficult 
than finding consistent prognostic markers. Several candidate molecular markers have been 
suggested, including BRAF, KRAS or TP53 mutation, microsatellite instability, CpG island 
methylation status (Brenner et al., 2014). To date, however, none of these markers has been 
validated in prospective trials. Accordingly, insufficient evidence was declared by current 
European guidelines for the treatment of CRC to recommend any molecular predictive 
marker for the response to 5-FU (Brenner et al., 2014; Schmoll et al., 2012).  
A link between inflammation and human colorectal cancer is now well established and, 
while the mechanism was not been completely understood, it is clear that immune and 
inflammatory cells actively participate in the tumor microenvironment and display both 
anti-tumor and pro-tumor activities (Grivennikov et al., 2010; Grivennikov et al., 2012; 
Terzic et al., 2010). A number of evidence have described several roles for cytokines and 
immune cells in the various steps of colorectal carcinogenesis, inducing initiation, 
81 
 
promotion and progression through metastatic disease. Therefore, efforts have been made to 
identify new biomarkers related to tumor environment and infiltration of immune and 
inflammatory cells (Grizzi et al., 2013). In particular, the presence of a type I adaptive 
immune response and the infiltration of T lymphocytes have been associated with a positive 
clinical outcome (Galon et al., 2006; Galon et al., 2007).  
As a well-known leukocyte subpopulation, neutrophils have long been recognized as a 
first-line defense against pathogens. Because of their short half-life and terminally 
differentiated phenotype, the role of neutrophils in tumor development has been considered 
negligible. However, epidemiological studies and animal models now suggest that 
neutrophils can be characterized by a surprising plasticity and can be polarized towards 
distinct phenotypes in response to signals derived from the tumor microenvironment 
(Fridlender et al., 2009). In addition, recent evidence suggests important roles of 
neutrophils in modulating tumor behavior and, similarly to their big brother macrophages, 
also neutrophils infiltrate human tumors (Donskov, 2013).  
High density of intra- or peritumoral neutrophils have been related to a worse disease 
outcome in HCC (n=238), melanoma (n=186), lung cancer (N=632) and head and neck 
cancer (N=99) (Ilie et al., 2012; Jensen et al., 2012; Kuang et al., 2011; Trellakis et al., 
2011a). Along similar lines, tumor-infiltrating neutrophils predicted poor prognosis in a 
cohort of gastric carcinoma patients (N=115) (Zhao et al., 2012), but were described as a 
positive prognostic factor in a second cohort of gastric cancer patients (N=273) (Caruso et 
al., 2002).  
With regard to colorectal cancer, few studies examined the prognostic significance of 
tumor infiltrating neutrophils (Table 3). In three of these studies, a higher neutrophil 
density was associated with better survival (Baeten et al., 2006; Klintrup et al., 2005; 
Nielsen et al., 1999). In the study of Baeten and colleagues, neutrophils were identified as 
CD16
+ 
cells and significant association between intratumoral CD16
+
 cells and patient 
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survival was observed (Baeten et al., 2006). In another study, neutrophil infiltration was 
related to reduced local recurrence rates, but not to survival (Nagtegaal et al., 2001). In 
addition to the study by Nagtegaal and colleagues, Klintrup et al. reported that an increased 
neutrophil infiltration at the invasive margin was found to be a prognostic factor, although 
both studies reported a positive prognostic role of other cell types and concluded that a 
general non-specific immune response was important in predicting patient survival 
(Klintrup et al., 2005). However, in all these studies, the prognostic significance of tumor-
infiltrating neutrophils was not confirmed by multivariate analysis (Baeten et al., 2006; 
Klintrup et al., 2005; Nagtegaal et al., 2001; Nielsen et al., 1999). In 2012 Rao and 
colleagues published the first report describing a high intratumoral neutrophil density as an 
adverse prognostic factor for patients with CRC (Rao et al., 2012). Indeed, in 229 patients 
undergoing primary resection for CRC, high intratumoral CD66b
+
 neutrophil count was 
positively associated with clinical stage. In multivariate survival analysis, high intratumoral 
neutrophils were described as an independent prognostic factor for adverse overall survival 
(Rao et al., 2012). In contrast, in 2013, Droeser and colleagues reported that intratumoral 
MPO
+
 neutrophils were associated with improved survival and confirmed this result by 
multivariate analysis in a wide cohort of CRC patients (N=1491) (Droeser et al., 2013). 
The described discrepancies between these studies can be explained by a number of 
variables. 
First of all, the methodology used to identify neutrophils within human tumors is an 
important point. Indeed, it is important to note that there was no consensus on the method 
for the staining of neutrophils in CRC tissues, since hematoxylin-eosin and 
immunohistochemistry were used in previous studies. Even when immunohistochemistry 
was used, a wide heterogeneity in the choice of the neutrophil-specific marker was found 
(CD16, elastase, MPO, CD15, CD66b). In addition, the method of assessment of neutrophil 
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count is also important, since semi-quantitative or quantitative scales as well as computer 
aided methods were arbitrarily used in these studies. 
In our study, we described that CD66b is a more specific marker for neutrophils in CRC 
tissues, compared to MPO, and should be used in further studies.  
In addition, we took advantage of a computer-aided image analysis system. This method 
is objective and statistically relevant to quantify the proper threshold values, because of 
providing detailed and informative data and continuous quantification of immune cell 
densities.  
Moreover, in our study, we analyzed a validated cohort of patients (Laghi et al., 2009) 
with long follow-up and known adjuvant treatment status. We showed that infiltration of 
neutrophils in colorectal cancer evolved overtime through a spatiotemporal dynamism. 
Indeed, neutrophil infiltration increased form stage I to stage III, followed by a decrease in 
stage IV. This result was in line with previous findings based on tissue microarrays data 
(Bindea et al., 2013). In addition, infiltration of neutrophils in stage III CRC patients was 
not spatially homogenous and was found higher in the intratumoral compartment compared 
to the invasive margin.  
By using a rigorous approach based on the detection of neutrophils (CD66b
+
 cells) found 
in both the invasive margin and the intratumoral compartment, we observed that higher 
densities of neutrophils were significantly associated with better clinical outcome in 
patients with CRC (stage I to Stage IV). However, this observation could be biased by the 
heterogeneity of the population and in particular by the chemotherapy treatment. Indeed, an 
additional level of heterogeneity among the studies could be due to the patient dataset 
analyzed. In contrast to the previous studies, we analyzed the prognostic role of neutrophils 
both for patients treated by surgery alone and for those who received 5-fluorouracyle (5-
FU) based chemotherapy. Indeed, investigation of the prognostic significance of clinic-
pathologic markers in stage III CRC patients treated with 5-FU revealed that tumor-
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infiltrating neutrophil density could be considered as a predictive factor for good response 
to 5-FU based chemotherapy. Indeed, we observed that infiltration of neutrophils within the 
intratumoral compartment was significantly associated with better clinical outcome in 5-FU 
treated patients (HR 0.42; 95% CI 0.21 to 0.83; p= 0.01) but not in patients treated with 
surgery alone (HR 1.79; 95% CI 0.64 to 4.99; p= 0.26).  
Our results support the relevance of evaluating patient cohorts with the same adjuvant 
treatment status when studying the prognostic role of pathologic and molecular markers in 
disease outcomes. Our findings can be interpreted considering that tumor-infiltrating 
neutrophils are a novel predictive factor for 5-FU-based chemotherapy response.  
However, careful examination is needed when evaluating prognostic markers by using 
subgroup analyses. Indeed, a differential prognostic power of a marker in distinct patient 
subgroups does not mean that the prognostic power of the marker differs on the basis of the 
variable that identifies subgroups (i.e. treatment). To efficiently demonstrate an effect 
modification of immune cells on chemotherapy treatment in predicting patients’ clinical 
outcome, it should be investigated the existence of an interaction between these two 
variables at multivariate analysis (Altman et al., 2012). In our study, we found that a 
statistical interaction between IT CD66b
+
 IRA and 5-FU-based treatment (p=0.009), thus 
further supporting the differential results obtained in patients subgroups. 
Previous works have suggested that the tumor immune environment can influence 
chemotherapy treatment and infiltration of adaptive immune cells was associated with 
chemotherapy response (Anitei et al., 2014a; Di Caro et al., 2013; Halama et al., 2011; Ma 
et al., 2013a; Medina-Echeverz et al., 2011). To the best of our knowledge, our study is the 
first to demonstrate a significant association between infiltration of innate immune cells and 
chemotherapy response in CRC patients. These data could also explain, at least in part, the 
discrepancies in results concerning the prognostic value of neutrophil infiltration in CRC 
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because, in the previous studies, authors do not have taken into account the treatment 
(Bindea et al., 2013; Droeser et al., 2013; Rao et al., 2012; Roncucci et al., 2008).   
Solid tumors are characterized by an inflammatory profile and the presence of infiltrated 
leukocytes. However, the significance and role of neutrophils in cancer development is still 
a matter of debate and a dual role for neutrophils in tumor biology has been described 
(Galdiero et al., 2013a). For instance, neutrophils were involved in genetic instability, 
which can favor neoplastic transformation and the acquisition of a metastatic phenotype, as 
well as in tumor angiogenesis (Jablonska et al., 2010; Jaillon et al., 2013; Scapini et al., 
2004; Shojaei et al., 2009). In contrast, neutrophils can acquire a cytotoxic phenotype to kill 
tumor cells and recent evidence suggests that tumor-infiltrating neutrophils can stimulate 
the T cell-dependent anti-tumoral immunity (Eruslanov et al., 2014; Granot et al., 2011).  
Here, we observed that the degree of neutrophil infiltration increased with the clinical 
stage. Accordingly, we found that CRC cells produce soluble factors able to recruit, 
prolong the lifespan and activate neutrophils. We found that CRC cells constitutively 
produced CXCL8, CXCL1 and CXCL2 and, accordingly, conditioned media from CRC 
cells exerted chemotactic activity towards neutrophils in a CXCR1/2-dependant manner. In 
addition, we found that CRC cells activated neutrophils and prolonged their survival 
through the production of GM-CSF. The expression of GM-CSF in CRC tissue was 
predominantly associated with tumor cells and its role in cancer was debated because this 
cytokine was involved in the generation of myeloid-derived suppressor cells (Marigo et al., 
2010). However, GM-CSF was recently associated with increased survival in patients with 
colorectal cancer (Nebiker et al., 2014). In the light of our data, this association between 
GM-CSF and patients’ outcome could be related with the capacity of GM-CSF to activate 
and increase the lifespan of neutrophils.  
Mirroring the M1-M2 and Th1-Th2 paradigms, recent evidences have suggested that 
mouse neutrophils could be polarized toward a proinflammatory phenotype with anti-tumor 
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activity (N1) or toward a pro-tumor N2 phenotype (Fridlender et al., 2009; Jablonska et al., 
2010). Here, we showed that human neutrophils display a cytostatic activity towards CRC 
cell lines. On the basis of the phenotype observed in CRC cell lines in the presence of 
neutrophils, one could hypothesize that an induced arrest of both cell death and 
proliferation occurs, via a mechanism named cellular senescence. Indeed, in the presence of 
cell damage, damage sensor proteins, such as Ataxia Telangectasia Mutated (ATM) protein, 
up-regulate effectors of cell cycle arrest (Herbig et al., 2004).  A number of stress inducers 
can activate this DNA damage response (DDR), including oxidants and DNA damaging 
chemotherapies. For instance, low doses of ROS activate senescence in human fibroblasts 
(Chen et al., 2000; Herbig et al., 2004). There is now strong evidence that cellular 
senescence is a potent anticancer mechanism (Braig and Schmitt, 2006; Prieur and Peeper, 
2008). However, further investigations are needed to gain deeper inside the mechanisms of 
the observed cytostatic effects exerted by neutrophils towards CRC cell lines. 
A direct link between our in vitro data and the clinically significant findings of our study 
should take into account that the primary tumor was surgically resected. Indeed, the 
cytostatic activity of neutrophils can be achieved beyond the primary site, as suggested in 
mouse (Granot et al., 2011). Therefore, we found that the density of neutrophils found in 
metastatic lymph nodes mirrored their density in the primary tumor, suggesting that 
neutrophils can exert their cytostatic functions in the metastatic niche.  
Even though this study presents some limitations due to the retrospective design and the 
small number of patients, it highlights the importance of the immune system and its 
interaction with chemotherapy for orientating the prognosis of localized colorectal cancer, 
suggesting that a precise evaluation of the local immune response could be useful for 
predicting prognosis in the context of chemotherapy.  
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Finally, we demonstrated that innate immunity and neutrophils have predictive 
significance for chemotherapy response in patients with stage III CRC and exert a direct 
cytostatic activity towards CRC cells. 
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FIGURES 
Figure 1. 
 
Figure 1. The hallmarks of cancer. This figure represents the six hallmarks originally proposed by 
Hanahan andWeimberg in 2000.     from Hanahan and Weimberg, 2011 
 
 
Figure 2. 
 
 
 
 
 
 
 
Figure 2. Emerging hallmarks and enabling characteristics. Two additional hallmarks are involved in 
the pathogenesis of cancers. One involves the ability to modify cellular metabolism and the second 
allows cancer cells to evade immunological surveillance. In addition, two characteristics favor 
acquisition of these hallmarks: genomic instability and cancer related inflammation.  
  
from Hanahan and Weimberg, 2011 
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The three phases of immunoediting. Cancer immunoediting results from three processes 
that occur independently or in sequence to control and shape cancer. In the first phase, elimination, 
previously known as cancer immunosurveillance, immune cells recognize and destroy transformed 
cells. If anti-tumor immunity is unable to completely eliminate transformed cells, surviving tumor 
variants may enter into the equilibrium phase. These variants may acquire further mutations that 
result in evasion of tumor cell recognition and killing by the immune system. Therefore cancer 
progresses to clinically detectable malignancy in the escape phase. 
from Vesely et al., 2011 
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Figure 4.  
 
 
 
 
 
 
 
 
Figure 4. The orchestration of macrophage polarization and their effector functions. 
(a) M1-polarized macrophages and their crosstalk with Th1 and NK cells. (b) M2 polarization of 
macrophages driven by IL-4, IL-13 or IL-33; (c) M2-like macrophages polarized by interaction with 
Treg cells. (d) M2-like polarization of macrophages by interaction with B cells through antibody- 
mediated FcγR activation or cytokines.     from Biswas and Mantovani, 2010 
 
 
Figure 5.  
 
 
 
 
 
 
 
Figure 5. TAMs as key regulators of the tumor-related inflammation. Neoplastic cells recruit 
macrophages, favoring their polarization toward a pro-tumor phenotype. In turn, TAMs influence 
many aspects of cancer progression, such as tumor growth, ECM remodeling, angiogenesis and 
immunosuppression.         
from Galdiero et al., 2013b 
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Figure 6.  
 
 
 
 
 
 
 
Figure 6. Schematic representation of proteins contained within neutrophil granule subsets.  
Modified from Eyles et al., 2006 
 
Figure 7. 
 
 
 
 
 
 
 
 
Figure 7. Dual role of TANs in tumor growth and progression. TANs can exert both anti-tumoral 
and pro-tumoral activities. TANs kill cancer cells through the release of ROS and neutrophil 
elastase, inhibit metastatic seeding through the release of ROS and potentiate anti-tumoral T cell 
responses after inhibition of TGF-β. In contrast, TANs favor genetic instability through the release of 
ROS, promote tumor cell proliferation through elastase, sustain angiogenesis through the release of 
VEGF, MMP-9 or Bv8, enhance neoplastic cell invasiveness through soluble mediators (e.g. OSM 
and HGF) and suppress effective anti-tumoral CD8
+
 T-cell immunity through the expression of 
arginase-1 driven by TGF-β. 
from Galdiero et al., 2013a 
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Figure 8. 
 
 
 
 
 
 
 
Figure 8. Genes and growth factor pathways that drive the progression of colorectal cancer. 
In the progression of colon cancer, genetic alterations target the genes that are identified. The 
microsatellite instability (MSI) pathway is initiated by MMR gene mutation or by aberrant MLH1 
methylation and is further associated with downstream mutations (i.e. TGFBR2 and BAX). The 
question mark indicates that genetic or epigenetic changes specific to metastatic progression have not 
been identified. Key growth factor pathways that are altered during colon neoplasia are shown at the 
bottom of the diagram.       from Markowitz and Bertagnolli, 2009 
 
Figure 9. 
 
 
 
 
 
 
 
Figure 9. Molecular pathogenesis of sporadic colon cancer (top) and colitis-associated 
colorectal cancer (bottom). There are similarities between the pathways, including the development 
of aneuploidy (CIN), MSI, DNA methylation, activation of the oncogene k-ras, activation of COX-2, 
and mutations of p53, APC. However, the frequency and sequence of these events differs between 
the cancers.  
from Ullman and Itzkowitz, 2011 
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Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Analysis of neutrophil infiltration in CRC tissue sections.  
A. Immunostaining analysis for CD68 (red) and MPO (green) (upper panel) and CD66b (red) and 
MPO (green) (lower panel) in CRC tissue sections. Double positive cells for MPO and CD68 were 
indicated by arrows (magnification: 40x). Bar: 50 µm B. Histological analysis of CRC samples stained 
with monoclonal anti-CD66b antibody. Density of neutrophils was analyzed in the invasive margin of 
the tumor (upper panel) and in the intratumoral compartment (lower panel) (magnification: 10X). Bar: 
200 µm C. CD66b
+
 immunoreactive area found in whole tumor sections (IM and IT) of patients with 
stage I (n=19), stage II (n=43), stage III (n=35) and stage IV (n=31) CRC.  
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Figure 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Prognostic significance of CD66b
+
 IRA in patients with Stage I-Stage IV CRC.  
A-D. Kaplan-Meier survival curves showed DSS (A-B) and DFS (C-D) for patients (n=128) with high 
or low density of neutrophils (CD66b
high 
or CD66b
low
, respectively) found in the IM or in the IT. ROC 
curve analysis was employed to define the cut-off values of the CD66b
+
 immunoreactive area. 
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Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Predictive significance of neutrophil infiltration for 5-FU chemotherapy response   
A. CD66b
+
 IRA in the IM and in the IT of tumor sections from patients with stage III CRC (n=178). 
B. Correlation between the CD66b
+
 IRA found in primary tumor and in metastatic lymph nodes in 
patients with stage III CRC. * P ≤ 0.05; Spearman’s correlation. C-E. Kaplan-Meier survival curves 
showed DFS for stage III CRC patients with high density of neutrophils or low density of neutrophils 
(CD66b
high 
or CD66b
low
, respectively) found in the IT. Curves were plotted for 5-FU treated patients 
(n=126) (C), 5-FU non-treated patients (n=52) (D) and combined 5-FU treated and non-treated 
patients (n=178) (E).  
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Figure 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Colorectal cancer cells recruit neutrophils 
A. Chemotactic activity of CM form CRC cell lines towards human freshly isolated neutrophils was 
evaluated by using a Boyden chamber. 20 high power oil-immersion fields were counted for each 
condition in triplicates. Results are mean ± SEM (n=4). * P ≤ 0.05; two-tailed Student’s t test. B-D. 
Production of CXCL8 (B), CXCL1 (C) and CXCL2 (D) by SW480, HT29 and SW620 was evaluated 
by ELISA in CRC CM. Once cells had reached a confluence of 85-90%, cell culture media were 
replaced by fresh media and supernatants were harvested after 24 h. Results are mean ± SEM (n=4). 
D. Chemotactic activity of CM from CRC cells towards freshly isolated neutrophils was analyzed in 
the presence of Reparixin (i.e. inhibitor of CXCR1/CXCR2), SB225002 (non-peptide inhibitor of 
CXCR2) or the G-coupled receptor inhibitor, PTX. Results are mean ± SEM (n=4). * P ≤ 0.05; two-
tailed Student’s t test.  
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Figure 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Neutrophil survival and morphological changes.  
A. Freshly isolated human neutrophils were cultured in CM from indicated CRC cell lines. Apoptosis 
was analyzed at different time points by flow cytometry using APC-labeled Annexin V binding and 
PI. Results are mean ± SEM (n=4). *P ≤ 0.05; Cusik’s trend test. B. Production of GM-CSF by 
SW480, HT29 and SW620 was evaluated by ELISA in cell supernatants. Once cells had reached a 
confluence of 85-90%, cell culture media were replaced by fresh media and supernatants were 
harvested after 24h. Results are mean ± SEM (n=4). C-D. Freshly isolated human neutrophils were 
cultured in CM from indicated CRC cell lines for 24h and in the presence of blocking monoclonal 
anti-GMCSF antibody or isotype control. Apoptosis was analyzed by flow cytometry using APC-
labeled Annexin V binding and PI (C). Results are mean ± SEM (n=4) ** P ≤ 0.01; two-tailed 
Student’s t test. Cell morphology was assessed by phase-contrast microscopy (magnification: 40X) 
(D).  Results shown are representative of four experiments.  
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Figure 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Cytostatic activity of neutrophils 
A-C. Freshly isolated neutrophils were pre-incubated with CM or control medium and added to CFSE-
labeled HT29 cells at ratio of 20:1. As positive control, HT29 cells were cultured in presence of 5-FU 
(5 µM). A-B. After 24h, total HT29 cell number (A) and percentage of apoptotic HT29 cells (B) were 
evaluated by flow cytometry with APC-conjugated Annexin-V. Results are mean ± SEM (n=4) * P ≤ 
0.05; ** P ≤ 0.01; *** P ≤ 0.001; two-tailed Student’s t test. C. MFI of CFSE-labeled HT29 cells was 
analyzed by flow cytometry. Results are mean ± SEM (n=4) ** P ≤ 0.01; *** P ≤ 0.001; two-tailed 
Student’s t test. 
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TABLES 
 
Table 1. Phenotype, characteristics and functions of relevant human T cell subsets. 
     T cell subset 
 
Phenotype 
 
Characteristic 
cytokine 
Characteristic 
transcription 
factors 
Functions 
 
Naive CD45RA+CCR7+ IL-2  Precursor cells, protection 
against pathogens 
TCM (central memory) CD45RA-CCR7+ IL-2, IL-21  Secondary expansion, help 
TEM (Effector memory) CCR7- IFN-g, IL-4, IL-5, 
IL-17 
 Protection in tissues, help 
TRM (Tissue-resident 
Memory) 
CD103+CD69+ IFN-g  Immediate protection in tissues 
TFH (Follicular Helper) CXCR5+ ICOS+ IL-21 BCL6 B cell help 
Th1 CXCR3+ IFN-g T-bet Protection against intracellular 
pathogens 
Th2 CRTH2+ IL-4, IL-5, IL-13 GATA3 Protection against extracellular 
parasites 
Th9 ? IL-9 PU.1 Protection against extracellular 
parasites 
Th17 CCR6+CD161+ IL-17, IL-22,  
IL-26 
RORC2 Protection against extracellular 
bacteria and fungi 
Treg CD25+CD127- TGF-b FOXP3 Maintenance of self tolerance 
Tr1 (Type 1 regulatory) CD25-CD127- or 
CD49b+ LAG3+ 
IL-10 ? Inhibition of immunopathology 
 
from Geginat et al., 2014 
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Table 2. Neutrophil-derived cytokines 
CXC chemokines CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL8, CXCL9, 
CXCL10, CXCL11, CXCL12*, CXCL13* 
CC chemokines CCL2, CCL3, CCL4, CCL17, CCL19, CCL20, CCL22 
Pro-inflammatory cytokines IL-1α, IL-1β, IL-6#, IL-7, IL-16, IL-17A, IL-17f#, IL-18, MIF 
Anti-inflammatory cytokines IL-1RA, IL-4
#
, IL-10
#
, TGF-β1, TGF-β2 
Immunoregulatory cytokines IFN-α§, IFN-β, IFN-γ#, IL-12, IL-23, IL-27, IL-21* 
Colony-stimulating factors G-CSF, M-CSF
#
, GM-CSF
#
, IL-3
#
, SCF
#,§
 
Angiogenic and fibrogenic 
factors 
HB-EGF, HGF, FGF-2, TGF-α, VEGF, Bv8 
TNF superfamily members APRIL, BAFF, CD30L, CD95L, LIGHT
§, LTβ§, RANKL, TNF, TRAIL, 
CD40L* 
Other cytokines Amphiregulin, BDNF
§
, midkine, NGF
§
, oncostatin M 
  Cytokines expressed by neutrophils, either spontaneously or following appropriate stimulation, based on gene 
expression techniques, immunohistochemistry, ELISA or biological assays in vitro or in vivo 
*. Reported expressed by "B-helper neutrophils" 
#. Controversial data for human neutrophils 
§. Studies performed at mRNA level only 
Modified from Jaillon et al, 2013 
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Table 3. Prognostic significance of tumor infiltrating neutrophils in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ref Tumor  
Type 
Method/Marker Location N Prognostic  
Impact 
Reid et al., 2011 Pancreas Hematoxylin- and eosin  Intratumoral 517 Negative 
Jensen H et al., 2009 RCC CD66b Intratumoral 121 Negative 
Li Y-W et al., 2011 HCC CD66b Intratumoral 281 Negative 
Kuang D-M. et al., 
2011 
HCC CD15 Peritumoral 
and 
Intratumoral 
200 Negative 
(Peritumoral) 
Jensen T. et al., 2011 Melanoma CD66b Intratumoral 186 Negative 
Ilie M. et al., 2011 NSCLC MPO, CD66b Intratumoral 632 NO, Negative 
Trellakis S. et al., 
2011 
HNSCC MPO, CD66b NS 99 NO, Negative 
Caruso et al., 2002 Gastric Hematoxylin- and eosin NS 273 Positive 
Zhao J. et al., 2012 Gastric CD15 Intratumoral 115 Negative 
Nielsen et al., 1999 CRC Hematoxylin- and eosin Peritumoral 584 Positive 
Nagtegaal ID et al., 
2001 
CRC Elastase Peritumoral 
and 
Intratumoral 
160 Positive 
(Peritumoral) 
Klintrup K et al., 
2005 
CRC Hematoxylin- and eosin Peritumoral 
and 
Intratumoral 
386 Positive 
(Peritumoral) 
Baeten C.I. et al., 
2006 
CRC CD16 Peritumoral 
and 
Intratumoral 
117 Positive 
(Intratumoral) 
Rao H-L. et al., 2012 CRC CD66b Intratumoral 229 Negative 
Richards CH. et al., 
2012 
CRC Hematoxylin and eosin Peritumoral 130 NO 
Droeser et al., 2013 CRC MPO, CD15 Intratumoral 1491 Positive 
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Table 4. Classification of colorectal cancer according to local invasion depth (T), lymph 
node involvement (N) and presence of distant metastases (M) 
    Definition 
T stage 
  Tx 
 
No information about local tumor infiltration available 
Tis 
 
Tumor restricted to mucosa, no infiltration of lamina muscularis mucosa 
T1 
 
Infiltration through lamina muscularis mucosa into submucosa, no infiltration of lamina muscularis 
propria 
T2 
 
Infiltration into, but not beyond, lamina muscularis propria 
T3 
 
Infiltration into subsierosa or non-peritonealised pericolic or perirectal tissue or both; no infiltration 
of serosa or neighbouring organs 
T4a 
 
Infiltration of the serosa 
T4b 
 
Infiltration of the neighbouring tissued or organs 
N stage 
  Nx 
 
No information about lymph node involvement available 
N0 
 
No lymph node involvement 
N1a 
 
Cancer cells detectable in 1 regional lymph node 
N1b 
 
Cancer cells detectable in 2-3 regional lymph nodes 
N1c 
 
Tumor satellites in subserosa or pericolic or perirectal fat tissue, regional lymph nodes not involved 
N2a 
 
Cancer cells detectable in 4-6 regional lymph nodes 
N2b 
 
Cancer cells detectable in 7 or greater regional lymph nodes 
M stage 
  Mx 
 
No information about distant metastases 
M0 
 
No distant metastases detectable 
M1a 
 
Metastases to 1 distant organ or distant lymph node 
M1b 
 
Metastases to more than 1 distant organ or set of distant lymph nodes or peritoneal metastases 
 
Adapted from Brenner et al., 2014 
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Table 5. International Union for Cancer Control (UICC) and the American Joint 
Committee for Cancer (AJCC) TNM classification of CRC 
 
  T N M 
Stage 0 Tis N0 M0 
Stage I T1-T2 N0 M0 
Stage II T3-T4 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
Stage III Any N+ M0 
IIIA T1-T2 N1 M0 
 
T1 N2a M0 
IIIB T3-T4a N1 M0 
 
T2-T3 N2a M0 
 
T1-T2 N2b M0 
IIIC T4a N2a M0 
 
T3-T4a N2b M0 
 
T4b N1-N2 M0 
Stage IV Any Any M+ 
IVA Any Any M1a 
IVB Any Any M1b 
 
Adapted from Brenner et al., 2014 
 
  
104 
 
 
Table 6. Correlation between the patient demographics and clinicopathologic features 
and CD66b+ IRA (IM and IT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 N CD66b+ IRA IM   CD66b+ IRA IT  
  
Median value 
(IQR) 
P value* 
 
Median value 
(IQR) 
P value * 
Age at diagnosis 
(years)       
≤ 65 66 0.27 (0.52-0.07) … 
 
0.11 (0.36-0.03) … 
˃ 65 62 0.15 (0.70-0.06) 0.73 
 
0.11 (0.42-0.02) 0.47 
Sex 
      
Male 74 0.18 (0.60-0.07) … 
 
0.13 (0.35-0.03) … 
Female 54 0.15 (0.58-0.03) 0.92 
 
0.08 (0.42-0.01) 0.30 
Microsatellite status 
      
MSI 8 0.16 (1.28-0.11) … 
 
0.21 (0.49-0.04) … 
MSS 120 0.18 (0.57-0.06) 0.35 
 
0.10 (0.36-0.02) 0.70 
Anatomical site 
      
Colon 99 0.17 (0.58-0.06) … 
 
0.1 (0.36-0.02) … 
Rectum 29 0.2 (0.66-0.07) 0.70 
 
0.2 (0.42-0.04) 0.19 
Clinical Stage 
      
Stage I 19 0.39 (0.65-0.07) … 
 
0.08 (0.42-0.04) … 
Stage II 43 0.16 (0.36-0.08) 0.38 
 
0.13 (0.36-0.01) 0.85 
Stage III 35 0.39 (1.31-0.08) 0.97 
 
0.24 (0.46-0.05) 0.77 
Stage IV 31 0.07 (0.35-0.03) 0.15 
 
0.08 (0.33-0.01) 0.35 
Grade 
      
G1-G2 110 0.17 (0.54-0.06) … 
 
0.1 (0.38-0.02) … 
G3 18 0.25 (1.22-0.06) 0.64 
 
0.2 (0.46-0.01) 0.72 
Tumor Cell Type 
      
Adenocarcinoma 119 0.20 (0.58-0.06) … 
 
0.13 (0.37-0.02) … 
Variants 9 0.11 (0.81-0.06) 0.60 
 
0.08 (0.46-0.03) 0.78 
Vascular Invasion 
      
No 94 0,29 (0,92-0,07) … 
 
0.13 (0.46-0.02) … 
Yes 34 0,095 (0,35-0,03) 0.06 
 
0.10 (0.27-0.01) 0.26 
 
* Linear regression analysis: % CD66b+IRA was entered as a dependent, continuous variable. 
Abbreviation: IRA, Immunoreactive area; IM, invasive margin; IT, intratumoral compartment; 
IQR, interquartile range 
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Table 7. Univariate and multivariate analysis for DSS and DFS in patients with 
colorectal cancer  
 
 
(α) Age entered as a continuous variable. Abbreviation: IRA, Immunoreactive area; IM, invasive margin; IT, intratumoral 
compartment; HR: Hazard Ratio; CI, confidence interval 
 
 
  
 
DSS 
 
DFS 
 
Univariate analysis 
 
Multivariate 
analysis  
Univariate analysis Multivariate analysis 
 
N 
HR  
(95% CI) 
P-value 
 
HR  
(95% CI) 
P-value 
 
HR  
(95% CI) 
P-value 
 
HR  
(95% CI) 
P-value 
Age at diagnosis 
(years)  
65.2±12.5 
0.98  
(0.96-1.00) 
0.12 
 
  
 
0.99  
(0.97-1.01) 
0.71 
 
  
Sex 
    
  
    
  
Male 74 1.00 ref 
  
  
 
1.00 ref 
  
  
Female 54 
0.87  
(0.53-1.45) 
0.60 
 
  
 
0.92  
(0.56-1.52) 
0.75 
 
  
Microsatellite 
status             
MSS 120 1.00 ref 0.05* 
 
NA NA 
 
1.00 ref 0.01* 
 
NA NA 
MSI 8 0.10 
     
0.06 
    
Anatomical 
location             
Colon 99 1.00 ref 
  
  
 
1.00 ref 
  
  
Rectum 29 
1.04  
(0.58-1.86) 
0.90 
 
  
 
0.97  
(0.54-1.73) 
0.91 
 
  
Clinical Stage 
            
I 19 1.00 ref 
  
1.00 ref 
  
1.00 ref 
  
1.00 ref 
 
II 43      
 
2.94  
(0.63-13.63)   
  
  
III 35 
3.85  
(2.76-5.37) 
<0.001 
 
4.55  
(2.84-7.28) 
<0.0001 
 
8.52  
(1.97-36.93) 
0.004  
2.80  
(2.03-3.86) 
<0.0001 
IV 31 
 
 
 
  
 
29.18  
(6.96-122.34) 
  
  
 
 
Tumor Grade 
            
G1-G2 110 1.00 ref 
  
  
 
1.00 ref 
  
  
G3 18 
1.41  
(0.72-2.77) 
0.32 
 
  
 
1.26  
(0.64-2.48) 
0.50 
 
  
Tumor cell type 
    
  
    
  
Adenocarcinoma 119 1.00 ref 
  
  
 
1.00 ref 
  
  
Variants 9 
1.14  
(0.49-2.68) 
0.75 
 
  
 
1.28  
(0.55-2.98) 
0.56 
 
  
Vascular Invasion 
            
No 94 1.00 ref 
  
1.00 ref 
  
1.00 ref 
    
Yes 34 
3.27  
(1.98-5.4) 
<0.001 
 
2.76  
(1.47-5.16) 
0.001 
 
3.22  
(1.95-5.33) 
<0.001 
 
  
 
CD66b+ IRA IM 
            
Low 65 1.00 ref 
  
  
 
1.00 ref 
  
  
High 63 
0.37  
(0.19-0.72) 
0.003 
 
  
 
0.55  
(0.32-0.94) 
0.030 
 
  
CD66b+IRA IT 
            
Low 63 1.00 ref 
  
1.00 ref 
  
1.00 ref 
  
1.00 ref 
 
High 65 
0.47  
(0.25-0.87) 
0.002 
 
0.47  
(0.25-0.91) 
0.03 
 
0.56  
(0.32-0.96) 
0.03 
 
0.58  
(0.33-1.00) 
0.05 
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Table 8. Univariate and multivariate analysis of different prognostic factors in 178 Stage 
III MSS CRC patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Univariate analysis Multivariate analysis 
 
N 
HR 
(95% CI) 
P value 
 
HR 
(95% CI) 
P value 
Age at surgery (years) 178 
     
< 68 97 1.00 ref 
  
  
>=68 81 
1.69 
(1.02-2.78) 
0.04 
 
  
Sex 
    
  
Male 108 1.00 ref 
  
  
Female 70 
1.04 
(0.62-1.73) 
0.87 
 
  
Anatomical location 
    
  
Colon DX 50 1.00 ref 
  
  
Colon SX 75 
0.68 
(0.36-1.26) 
0.22 
 
  
Rectum 53 
1.09 
(0.59-2.02) 
0.77 
 
  
Tumor Grade 
      
G1-G2 144 1.00 ref 
  
1.00 ref 
 
G3 34 
2.35 
(1.36-4.04) 
0.002 
 
2.12 
(1.21-3.75) 
0.009 
Tumor cell type 
      
Adenocarcinoma 165 1.00 ref 
  
  
Variants 13 
1.76 
(0.80-3.86) 
0.16 
 
  
Vascular Invasion 
      
No 123 1.00 ref 
  
1.00 ref 
 
Yes 55 
2.48 
(1.50-4.09) 
0.0004 
 
1.83 (1.07-3.12) 0.003 
Nodal Status 
      
N1 115 1.00 ref 
  
1.00 ref 
 
N2 63 
2.55 
(1.54-4.20) 
0.0002 
 
1.96 (1.16-3.30) 0.01 
Local Invasion 
      
T3 153 1.00 ref 
  
  
T4 25 1.2 (0.61-2.36) 0.59 
 
  
5-FU 
    
  
NO 52 1.00 ref 
  
  
YES 126 
0.61 
(0.36-1.02) 
0.06 
 
  
CD66b+IRA IT 
    
  
Low 131 1.00 ref 
  
  
High 47 
0.61 
(0.32-1.15) 
0.12 
 
  
*INTERACTION between 5-FU and CD66b P=0.009; HR= 0.17; 95% C.I. 0.05-
0.65; † Mean ± Std. Abbreviation: IRA, Immunoreactive area IM, invasive margin; 
IT,  intratumoral compartment 
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